

2023 ASCO Exhibitors

Pipelines & Contacts

Pharmaceutical Company

Aadi Bioscience



Booth : #4072 and #3073

CONTACT

PHONE :

1-888-246-2234

Email : medinfo@aadibio.com

Address :

17383 Sunset Blvd, Suite A250 Pacific
Palisades, CA 90272

WEBSITE : <http://www.aadibio.com>


No. of Employees : 34

Revenue : \$6 million

■ About Aadi Bioscience

Aadi Bioscience, Inc. is a biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations. FYARRO™ (sirolimus protein-bound particles for injectable suspension) (albumin-bound), is the first and only FDA approved therapy for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

■ Pipeline



Evaluation of additional new single agent and combination trials ongoing

● Ongoing ● To be initiated / In planning

Find out more about pipelines at <https://aadibio.com/pipeline-clinical-studies/>

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Abbvie



Booth : #14099

CONTACT

PHONE :

1-847-932-7900

Address :

1 North Waukegan Road North Chicago,
IL 60064 United States

WEBSITE : <https://www.abbvie.com>

No. of Employees : 50,000

Revenue : \$56.2 B

■ About AbbVie

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson's, and alzheimer's disease.

■ Approved AbbVie Product in Oncology

- VENCLEXTA : (venetoclax tablets for oral use)

■ Pipeline (>20 in oncology)

Oncology

Molecule Name	Potential Indication	Phase(1, 2, 3, Submitted)	
ABBV-011	Small Cell Lung Cancer	<div><div></div><div></div><div></div><div></div></div>	→
ABBV-151	Solid Tumors	<div><div></div><div></div><div></div><div></div></div>	→
ABBV-155	Solid and Hematologic Tumors	<div><div></div><div></div><div></div><div></div></div>	→
ABBV-181	Solid Tumors	<div><div></div><div></div><div></div><div></div></div>	→
ABBV-368	Solid Tumors	<div><div></div><div></div><div></div><div></div></div>	→
ABBV-383	Multiple Myeloma	<div><div></div><div></div><div></div><div></div></div>	→

Find out more about pipelines at <https://www.abbvie.com/our-science/pipeline.html>

Global offices

Research Centers :

USA, Germany, Japan

Manufacturing Sites :

USA, Ireland, Germany, Italy,
Singapore

Abbvie Office in South Korea

Address : 6th Floor, SamTan Bldg,
421 YoungDong-Daero,
Gangnam-gu, Seoul, 06182, Korea

Phone : +82.2. 3429. 9300

Fax : +82.1800.0354

Pharmaceutical Company

Acrotech Biopharma



Booth : #2098

CONTACT

PHONE : (866) 850-2876

E-mail : Info@AcrotechBiopharma.com

Address :

279 Princeton Hightstown

Rd. East Windsor, NJ 08520

인도 아우로빈도파마 자회사 제네릭마켓

WEBSITE :

<https://acrotechbiopharma.com/>

No. of Employees : 51-200

Revenue : \$11.2 M

■ About Acrotech Biopharma

Founded in 2018, Acrotech Biopharma LLC, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. The company aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

■ Products

Beleodaq [®] (belinostat) for injection 500 mg per vial for intravenous infusion	Prescribing Information Visit BELEODAQ.com
FOLOTYN [®] (pralatrexate injection) 20 mg/1 mL and 40 mg/2 mL single-dose vials	Prescribing Information Visit FOLOTYN.com
ZEVALIN [®] (ibritumomab tiuxetan) INJECTION FOR INTRAVENOUS USE 3.2 mg per 2 mL	Prescribing Information Visit ZEVALIN.com
Hemady [®] (dexamethasone) Tablets, 20 mg	Prescribing Information Visit HEMADY.com
Evomela [®] (melphalan) for Injection 50 mg per vial	Prescribing Information Visit EVOMELA.com
KHAPZORY [™] (levoleucovorin) for injection 175 mg per vial - 300 mg per vial	Prescribing Information Visit KHAPZORY.com

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Adaptive Biotechnologies Corporation



Booth : #21135

CONTACT

PHONE :
(206) 659-0067

Address :
1165 Eastlake Ave E
Seattle, WA 98109
research_sales@adaptivebiotech.com
WEBSITE :

<https://www.adaptivebiotech.com/>

No. of Employees : 622

Revenue : \$154.3 M

■ About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive's goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

■ Pipeline



Find out more about pipelines at

<https://www.adaptivebiotech.com/pipeline/#diagnostics>

Global offices

South San Francisco:
2 Tower Place, Suite 900 South
San Francisco, CA94080

New York"
1540 Broadway, Suite 3910 New
York, NY 10036

Office in South Korea

N/A

Biotechnology Company (Gene Testing)

Agendia



Booth : #22122

CONTACT

PHONE :

(888) 321-2732

E-mail : customercare@agendia.com

Address :

Agendia Inc. USA,
22 Morgan, Irvine,
CA 92618

WEBSITE : <https://agendia.com/>

No. of Employees : 107

Revenue : \$58.42 M

■ About Agendia

Agendia is a leading precision oncology company that develops genomic tests to help support physicians faced with complex treatment decisions. MammaPrint®, the 70-gene signature is an FDA-cleared breast cancer recurrence assay, backed by peer-reviewed, prospective outcome data and is included in many national and international guidelines. Blueprint®, the 80-gene molecular subtyping assay looks beyond the cell surface to identify Luminal-type, Basal-type and HER2-type breast cancer.

■ Clinical Science

- 1) Ongoing Trials
 - Flex Study
 - I-SPY2 Trial : adaptive model allowing multiple treatments
 - PRECiSE Study
- 2) Landmark Trials
 - MINDACT
 - STO-3
 - NBRST
 - NSABP B-42
 - IMPACT

Find out more about pipelines at <https://agendia.com/ongoing-trials/>

Global offices	Office in South Korea
Agendia NV, Radarweg 60. 1043 NT Amsterdam, The Netherlands	N/A

Pharmaceutical Company

Alkermes



Booth : #2068

CONTACT

PHONE : +353 1 772 8000

Address : Connaught House
1 Burlington Road
Dublin 4, Ireland, D04 C5Y6

WEBSITE : <https://www.alkermes.com/>

No. of Employees : 1,200

Revenue : \$1.17 B

■ About Alkermes

Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia, bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

■ Pipeline

Oncology

Nemvaleukin alfa* - *Platinum-Resistant Ovarian Cancer*




Nemvaleukin alfa - *Mucosal Melanoma*



IL-12



IL-18



*In combination with pembrolizumab
Last updated: February 2022

Discovery Preclinical Phase 1 Phase 2 Phase 3

Neuroscience


Olanzapine and samidorphan - *Schizophrenia or Bipolar I Disorder (pediatric)*



ALKS 2680 - *Narcolepsy*



HDAC Inhibitors - *Neurology/Neuropsychiatry*



Find out more about pipelines at <https://www.alkermes.com/research-and-development#pipeline>

Global offices

Waltham, MA
852 Winter Street

Monksland, Athlone

Wilmington, OH

Office in South Korea

N/A

Pharmaceutical Company

AMGEN



Booth : #18097

CONTACT

PHONE : +1 805-447-1000

Address : Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

WEBSITE :

<https://www.amgenoncology.com/medicinal.html>

No. of Employees : 22,000

Revenue : around \$26 billion

About Amgen

At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. We are dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer.

Pipeline: 20 in oncology/hematology

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
BEMARITUZUMAB	▼ Hematology / Oncology	Gastric and Gastroesophageal Junction (GEJ) Cancers	Monoclonal Antibody	3
	▼ Hematology / Oncology	Non-Small Cell Lung Cancer	Monoclonal Antibody	1
	▼ Hematology / Oncology	Other Tumors	Monoclonal Antibody	1
BLINCYTO® (blinatumomab)	▼ Hematology / Oncology	Acute Lymphoblastic Leukemia	BITE® Molecule	3
KYPROLIS® (carfilzomib)	▼ Hematology / Oncology	Multiple Myeloma	Small Molecule	3
	▼ Hematology / Oncology	Pediatric Acute Lymphoblastic Leukemia	Small Molecule	2
LUMAKRAS® (sotorasib)	▼ Hematology / Oncology	Advanced Colorectal Cancer	Small Molecule	3
	▼ Hematology / Oncology	Non-Small Cell Lung Cancer	Small Molecule	2
	▼ Hematology / Oncology	Other Tumors	Small Molecule	2
NPLATE® (romiplostim)	▼ Hematology / Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
ABP 959 (Investigational biosimilar to Soliris® (eculizumab))	▼ Hematology / Oncology	Investigational Biosimilar	Monoclonal Antibody	3

Find out more about pipelines at

<https://www.amgenoncology.com/pipeline.html#modality>

Global offices

N/A

Office in South Korea

서울시 중구 을지로 5 길, 19,
페럼타워 20 층

02-3434-4800

Medinfo.JAPAC@amgen.com

Pharmaceutical Company

AnHeart Therapeutics



Booth : #5043

CONTACT

PHONE : +1 678 892 1365

Address : 777 Third Avenue, Suite 1704

New York, NY 10017, USA

Tel: +1 212 466 6378

WEBSITE : www.anhearttherapeutics.com

bd@anhearttherapeutics.com

■ About AnHeart Therapeutics

AnHeart Therapeutics is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Lead asset taletrectinib, a potential best-in-class next-generation ROS1 inhibitor, is in pivotal Phase 2 trials in first-line and second-line patients with ROS1+ NSCLC and has received BTB from both the US FDA and China NMPA. Second asset safusidenib, a potential best-in-class brain-penetrant mIDH1 inhibitor, is in Phase 2 trials in patients with IDH1-mutated glioma. The US headquarter of AnHeart is in New York.

■ Pipeline

Taletrectinib/AB-106 – Phase 2 <i>a next-generation ROS1 inhibitor</i> ROS1 fusion-positive non-small cell lung cancer (NSCLC)	AB-218 – Phase 2 <i>a mIDH1 inhibitor</i> Lower grade glioma, cholangiocarcinoma and other tumors	AB-329 – Phase 1 <i>an AXL inhibitor</i> Combination therapy with checkpoint inhibitors or chemotherapy in NSCLC and other solid tumors
---	--	--

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

Arcus Biosciences



Booth : #24155

CONTACT

PHONE : N/A

E-mail : info@arcusbio.com

bd@arcusbio.com

Address : 1800 Sierra Point Parkway,
Brisbane, CA 94005

WEBSITE : <https://arcusbio.com/>

No. of Employees : 108

Revenue : \$37.9 million

About Arcus Bioscience

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a.

Pipeline

Indication	Study	Line & Regimen	Phase 1	Phase 1b	Phase 2	Phase 3
Lung Cancer	ARC-7	1L, PD-L1 ≥ 50% dom + zim + etruma vs. zim				
	EDGE-Lung	1L, 2L dom + zim + quermil + chemo				
	VELOCITY-Lung	1L, 2L dom + zim + etruma + sacituzumab govitecan				
	ARC-10	1L, PD-L1 ≥ 50% dom + zim vs. pembro				
	PACIFIC	Stage III, unresectable, PD-L1 ≥ 1% dom + durvalumab vs. durvalumab				
	STAR-19	1L dom + zim + chemo vs. pembro + chemo				
Prostate Cancer	ARC-6	2L+ etruma + zim + doce vs. doce etruma + sacituzumab govitecan + zim				
Pancreatic Cancer	ARC-8	1L quermil + zim + gem/nab-pac vs. quermil + gem/nab-pac				
		2L quermil + zim + gem/nab-pac				
Gastrointestinal Cancer	EDGE-Gastro	1L dom + zim + FOLFOX*				
	STAR-20	2L+ dom + zim				
Advanced Malignancies, Including RCC	ARC-20	1L dom + zim + chemo vs. niv + chemo				
		2L+ AB521				
Healthy Participants	ARC-14	AB521				

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

ARVINAS



Booth : # 22161

CONTACT

PHONE : +1 203 535 1456

E-mail : info@arvinas.com

bd@arvinas.com

Address : 5 Science Park 395
Winchester Ave. New Haven, CT
06511

WEBSITE : <https://www.arvinas.com/>


No. of Employees : 280

Revenue : \$46.70 million

■ About Avinas

Arvinas is a clinical-stage biotech company dedicated to improving the lives of patients suffering from life-threatening diseases through the discovery, development, & commercialization of targeted protein degradation therapeutics. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer PROTAC® targeted protein degraders, which are designed to harness the body's natural protein disposal system to selectively & efficiently degrade & remove disease-causing proteins. Arvinas has three clinical-stage programs and a robust preclinical pipeline of PROTAC® protein degraders.

■ Pipeline



Find out more about pipelines at <https://www.arvinas.com/pipeline-programs/pipeline>

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

Ascendis Pharma



Booth : # 19160

CONTACT

PHONE : +45 70 22 22 44
E-mail : BD@ascendispharma.com
bd@arvinas.com
Address : Tuborg Boulevard 12
2900 Hellerup
Denmark

WEBSITE : www.ascendispharma.com
No. of Employees : 280

Revenue : \$46.70 million

About

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Leveraging this strategic approach, we currently have a pipeline of three independent **endocrinology** rare disease product candidates in clinical development and we are advancing **oncology** as a second therapeutic area of focus. We continue to expand into new therapeutic areas to address unmet patient needs.

Pipeline



Find out more about pipelines at <https://ascendispharma.com/pipeline/>

Global Offices

1000 Page Mill Road
Palo Alto, CA 94304, USA
Tel: +1 650 352 8389

Office in Korea

N/A

Pharmaceutical Company

Ascentage Pharma



Booth : # 27161

CONTACT

PHONE : +86-512-85557777

E-mail : BD@ascentage.com

Address : 68 Xinqing Road, Suzhou
Industrial Park, Suzhou, Jiangsu, 215000

WEBSITE : www.ascentage.com

About

Ascentage Pharma is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Pipeline

Apoptosis Targets (Protein-Protein Interactions)			PRECLINICAL	PHASE I	PHASE II	FILED	MARKETED
+ Lisoftoclax APG-2575	Bcl-2 Selective	CLL/SLL					
		CLL/SLL					
		WM					
		T-PLL					
		AML					
	Bcl-2/Bcl-xL	MM					
		Solid Tumors					
		ER+/HER2- Breast Cancer					
		MDS					
		NSCLC + TKI					
+ Pelitoclax APG-1252	Bcl-2/Bcl-xL	MF					
		NET					
		Solid Tumors (IO combo)					
+ Alrizomadlin APG-115	MDM2-p53	AML,MDS					
		Solid tumors + IO					
+ APG-1387	IAP/XIAP	PDAC + Chemo					
		HBV					

Global Offices

US Head Office:

700 King Farm Blvd, Suite 510,
Rockville, MD 20850

T : +1 3012915658

Australia Office:

Suite 30.03, Level 30, 133
Castlereagh Street,

Sydney NSW 2000 Australia

T : +(61) 414 668 863

Pharmaceutical Company

Astellas Pharma US, Inc.



Booth : # 7134

CONTACT

PHONE : +81-3-3244-3000

Address : 2-5-1, Nihonbashi-Honcho,
Chuo-Ku, Tokyo 103-8411, Japan

WEBSITE :

<https://www.astellasoncology.com/>

No. of Employees : 17,217

Revenue : over 473 billion Japanese yen

About

Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Northbrook, Illinois, the company serves as the headquarters for the Americas and employs nearly 3,000 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Pipeline

Primary Focus	Generic Name Code No. (Brand Name)	Classification	Target Disease	Phase *	Licensor **
				1 2 3 F A	
Immunology-Oncology	ASP9801	Oncolytic virus carrying IL-7 and IL-12	Cancer		Tottori University [Discovered through collaborative research]
	ASP7517	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome		RIKEN [Discovered through collaborative research]
			Solid tumor		
	ASP0739	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer		RIKEN [Discovered through collaborative research]
	ASP1570	DGKζ inhibitor	Cancer		In-house
	ASP2138	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma		Xencor [Discovered through collaborative research]
	ASP2074	Bispecific antibody	Cancer		In-house
	ASP1002	Bispecific antibody	Cancer		In-house

Global Offices

2375 Waterview Drive

Northbrook, IL 60062-6111

Phone: 800-727-7003

Office in South Korea

위치: 서울시 강남구 테헤란로 521
파르나스타워 7 층

대표 번호: +82-2-3448-0504

Pharmaceutical Company

**Astex Pharmaceuticals,
Inc.**



Booth : #12089

CONTACT

PHONE : +44 (0) 1223 226200

E-mail : jeremy.carmichael@astx.com

Martin.buckland@astx.com

Address : 436 Cambridge Science
Park
Cambridge
CB4 0QA, UK

WEBSITE : <https://astx.com/>

No. of Employees : 156

Revenue : \$50 million

■ About

Astex Pharmaceuticals, Inc. ("Astex") is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of solid tumors and hematological malignancies. Astex is a member of the Otsuka group of pharmaceutical companies. The group also includes Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd and Taiho Oncology, Inc. Subject to regulatory approvals, Astex's products will be commercialized in the US and Canada by Taiho subsidiaries, and the rest of the world by Otsuka subsidiaries.

■ Pipeline



Find out more about pipelines at <https://astx.com/research-development/clinical-pipeline/>

Global offices

-US Corporate & Clinical
Development Headquarters

Tel: +1 925.560.0100

4420 Rosewood Drive Suite 200
Pleasanton, CA 94588, USA

Office in South Korea

N/A

Pharmaceutical Company

AstraZeneca



Booth : # 10027

CONTACT

PHONE : +44 (0)20 3749 5000

Email:

Address : AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA

WEBSITE :

No. of Employees : 83,100

Revenue : \$37.42 Billion

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology.

Technology

Oncology (as of 29 April 2022)			
Phase I	Phase II	Phase III	LCM Projects
AZD0466 haematological malignancies	adavosertib ovarian cancer, solid tumours, uterine sarcoma, cancer	camizestrant + CDK4/6i SERENA-6 for use with HER2-ESR1m breast cancer	Calquence + R-CHOP ESCALADE for use without stage B cell lymphoma
AZD1390 glioblastoma	AZD0171 + Imfinzi + CTx for use in metastatic pancreatic ductal adenocarcinoma	camizestrant + palbociclib SERENA-4 for use with HER2-breast cancer	Calquence + venetoclax + obinutuzumab AMPLIFY for use chronic lymphocytic leukaemia
AZD2936 solid tumours	AZD4573 haematological malignancies	capiasertib + abiraterone CAPitello-281 PTEN deficient metastatic hormone sensitive prostate cancer	Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
AZD5991 haematological malignancies	AZD4573 + Calquence haematological malignancies	capiasertib + CTx CAPitello-290 for use metastatic triple negative breast cancer	Calquence ECHO for use metastatic cell lymphoma
AZD7648 solid tumours	AZD5305 solid tumours	capiasertib + fulvestrant + palbociclib CAPitello-292 for use against in early stage/ET resistant locally advanced (inoperable) or metastatic breast cancer	Calquence ELEVATE-TN for use chronic lymphocytic leukaemia
AZD7789 solid tumours, haematological malignancies	camizestrant ovarian recurrence +/ve breast cancer	capiasertib + fulvestrant CAPitello-291 and line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer	Enhertu (platform) DESTINY-Breast07 HER2-low breast cancer
AZD8205 solid tumours	capiasertib prostate cancer	capiasertib + fulvestrant CAPitello-291 and line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer	Enhertu (platform) DESTINY-Breast08 HER2-low breast cancer
AZD8701 +/- Imfinzi solid tumours	cerasertib solid tumours	datopotamab deruxtecan TROPION-Breast01 p-M, HER2 breast cancer	Enhertu DESTINY-Breast02 HER2 positive, unresectable or locally recurrent breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
Imfinzi + adavosertib solid tumours	Imfinzi (platform) COAST non-small cell lung cancer	datopotamab deruxtecan TROPION-Lung01 2L+ NSCLC without actionable genomic mutations	Enhertu DESTINY-Breast03 HER2 positive, unresectable or locally recurrent breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
IPH5201 solid tumours	Imfinzi (platform) HUDSON post AD anti-HER2 cell lung cancer	Imfinzi + trems + TACE +/- Lenvatinib EMERALD-3	Enhertu DESTINY-Breast04 HER2 positive, unresectable or locally recurrent breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
MED11191 solid tumours	Imfinzi (platform) NeoCOAST non-small cell lung cancer		

For more detail, visit <https://www.astrazeneca.com/our-therapy-areas/pipeline.html>

Global offices

-Swedish Central Securities
Depository

SE-101 23 Stockholm

Sweden

Tel: +46 (0)8 402 9000

Office in South Korea

21F, Asem tower, 517 Yeongdong-daero, Gangnam-gu, Seoul,
Republic of Korea

LG Chem(모회사, 서울시 영등포구
여의대로 LG 트윈타워 128)

Pharmaceutical Company

AVM Biotechnology



Booth : # 7153

CONTACT

Our Address:

AVM Biotechnology
1749 Dexter Ave N
Seattle, WA 98109

Phone:

+1 (206) 906-9922

WEBSITE : <https://avmbiotech.com/>

No. of Employees : 35

Revenue : \$7.5 million

■ About AVM Biotechnology

AVM Biotechnology, a clinical stage company, advancing AVM0703 for expeditious FDA approval in patients with relapsed/refractory "no-option" Non-Hodgkin's Lymphoma/Leukemia. AVM0703 rapidly induces, expands, and mobilizes endogenous bispecific $\gamma\delta$ TCR+ invariant TCR+ NKT-like cells by a glucocorticoid-receptor-independent mechanism and potentiates chemotherapy and CAR-T response in pre-clinical models. Durable clinical responses have been achieved with no DLT's. Ph2/3 expected in NHL in 2022. Experienced leadership and innovation. Seeking strategic partner for commercial launch in 2023.

■ Technology

- AVM0703 & Cancer

AVM0703 rapidly triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a single dose of AVM0703. They home to abnormal cells including cancer, infected cells and autoreactive lymphocytes. It is clear that these cells could play a significant role in addressing several serious conditions.

The proprietary AVM0703 formulation is based on dexamethasone (DP), approved by the FDA at much lower doses since 1958.

AVM0703 has been engineered to permit very high doses of dexamethasone to be administered without concerning side-effects. The unique, higher dose AVM0703 formulation is required to deploy activated AVM-NKT cells into the bloodstream for targeted delivery to abnormal cells.

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Bayer



Booth : #10115

CONTACT

PHONE : +49 214 30-1

Email: N/A

Address : Bayer AG
51368 Leverkusen, Germany

WEBSITE :

<https://www.oncology.bayer.com/>

No. of Employees : 99,637

Revenue : \$52.152B

About Bayer

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. The oncology franchise at Bayer includes six marketed products across various indications and several compounds in different stages of clinical development. Bayer focuses its research activities on first-in-class innovations across the following scientific platforms: Precision Molecular Oncology, Targeted Alpha Therapies, and Immuno-Oncology. The company's approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Pipeline

Phase	Status	Description	Tumor Type(s)	
I	Now Enrolling	An Open-label, First-in-human Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of BAY 2927088 in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC). NCT03089172	Non-Small Cell Lung Cancer	+
III	Now Enrolling	An open-label, randomized, phase III study of docetaxel vs docetaxel and radium-223 for metastatic castration-resistant prostate cancer (DORA). NCT03574571	Prostate Cancer	+
IV	Now Enrolling	A Phase IV, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer Progressing on/After One Line of NAH. NCT04597125	Prostate Cancer	+
II	Now Enrolling	A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. (ARASEC). NCT05050636	Prostate Cancer	+
III	Now Enrolling	ARAMOTE: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer. NCT04736199	Prostate Cancer	+
III	Now Enrolling	NCI Sponsored - Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score. NCT02020364	Prostate Cancer	+
III	Now Enrolling	INTEGRATE II - A Randomized, Phase II, Double-Blind, Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-esophageal Cancer. NCT02777324	Advanced Tumors	+
III	Now Enrolling	DASL-HCGP: Darolutamide Augments Standard Therapy for Localized Very High-risk Cancer of the Prostate (ANZUP1801): A Randomized Phase II Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High-risk, Clinically Localized Prostate Cancer. NCT04130353	Prostate Cancer	+

For more information, visit <https://www.oncology.bayer.com/clinical-trials>

Global offices

100 Bayer Boulevard
Whippany, NJ 07981
USA
Phone: +1 862 404 3000

Office in South Korea

108, Yeoui-daero, Yeongdeungpo-gu,
Seoul, (Parc 1, Tower2)07335
Republic of Korea
Phone: +82-2-829-6600

Pharmaceutical Company

BeiGene



Booth : # 22097

CONTACT

PHONE : +1 (781) 801-1800

+1 (877) 828-5568

E-mail : info@beigene.com

Address : 55 Cambridge Parkway, Suite
700W Cambridge, MA
02142

WEBSITE : <https://www.beigene.com/>

No. of Employees : 8,200

Revenue : \$1.29 Billion

■ About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer.

■ Pipeline



Find out more about pipelines at <https://www.beigene.com/our-science-and-medicines/pipeline/>

Global offices

-China

Zhongguancun Life Science Park
Changping District, Beijing 102206

-Europe

BeiGene Switzerland GmbH
Aeschengraben 27
21st Floor

Office in South Korea

14F Gangnam Bldg. 396 Seocho-daero, Seocho-gu, Seoul 0661

Pharmaceutical Company

**Biolexis Therapeutics,
Inc.**



Booth : # 19115

CONTACT

PHONE : 801-692-3655

Address : 858 S Auto Mall Dr. #102

American Fork, UT 84003

United States

EMAIL: info@biolexistx.com

WEBSITE : <https://biolexistx.com/>

No. of Employees : N/A


Revenue : N/A

■ About Biolexis Therapeutics, Inc.

Biolexis' empirically developed MolecuLern™ technology enables rapid discovery and development of novel clinical candidate agents. Our modern chemical biology approach coupled with the real data power of machine learning (ML) and artificial intelligence (AI) are the key to accelerating our discoveries. Our world-class MolecuLern database is embedded with over five hundred thousand biochemical data points to help identify novel target fragment binding sites and then expand into IP rich high-value NCEs. MolecuLern additionally reduces therapeutics development costs and accelerates the development timeline while aiming to increase the probability of success in First-In-Human clinical trials.

■ Pipeline

MOLECULERN DRIVEN PIPELINE



Find out more about pipelines at <https://biolexistx.com/>

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Blueprint Medicines



Booth : # 26106

CONTACT

Blueprint Medicines Global Headquarters

45 Sidney Street

Cambridge, MA 02139

(617) 374-7580

info@blueprintmedicines.com

WEBSITE :

<https://www.blueprintmedicines.com>


No. of Employees : 383

Revenue : \$200 million

About Blueprint Medicines

Blueprint Medicines aims to make real the promise of precision therapy to improve and extend life for as many people with cancer and hematologic disorders as possible.

Pipeline



Find out more about pipelines at <https://www.blueprintmedicines.com/pipeline/>

Global offices

-EU Office

Blueprint Medicines (Switzerland)
GmbH Baarerstrasse 8

6300 Zug

Switzerland

Office in South Korea

N/A

Pharmaceutical Company

Boehringer Ingelheim Pharmaceuticals, Inc



Booth : # 15153

CONTACT

PHONE : 1-800-243-0127

900 Ridgebury Road
Ridgefield, CT 06877

Headquarter: Ingelheim, Germany

WEBSITE : <https://www.boehringer-ingelheim.us/>

No. of Employees : 52,000

About

At Boehringer Ingelheim we are taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer.

Pipeline



For more information, visit <https://www.boehringer-ingelheim.us/human-pharma/pipeline/our-human-pharma-research-and-development-pipeline>

Global offices

China, Austria, Germany, etc

Office in South Korea

서울특별시 중구 통일로 10,
연세재단 세브란스 빌딩 16 층
(우편번호: 04527)

전화번호 : (02) 709-0112

Pharmaceutical Company

Bristol Myers Squibb



Booth : # 10063, and #4024

CONTACT

PHONE : 1-800-332-2056

Address : Bristol Myers Squibb
Corporate Headquarters 430 E. 29th
Street, 14th Floor, New York, NY 10016

WEBSITE : <https://www.bms.com/>

No. of Employees : 30,000

Revenue : \$11.4 billion

■ About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

■ Approved Bristol Myers Squibb Product

- ABECMA : (idecabtagene vicleucel)
- ABRAXANE : (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
- AZACTAM : (aztreonam for injection, USP)

For more information, please visit <https://www.bms.com/patient-and-caregivers/our-medicines.html>

■ Pipeline

Our pipeline at a glance

As of April 27, 2023

50+

Compounds in development

40+

Disease areas being studied

Find out more about pipelines at <https://www.bms.com/researchers-and-partners/in-the-pipeline.html>

Global offices

Europe, APAC, USA, etc

Office in South Korea

504 Teheran-ro, 대치 2 동
Gangnam-gu, Seoul

[02-3404-1300](tel:02-3404-1300)

Pharmaceutical Company

Canaria Bio



Booth : # 24174

CONTACT

PHONE : 041-563-8200~4

Website: <https://canariabio.com/>

Address : 충남 천안시 동남구 용수골길
23(용곡동)

WEBSITE : <https://canariabio.com/>

About

CanariaBio is a biotechnology company with assets for research and development of immuno-anticancer treatments. We have pipelines for the development of various immunotherapeutic for ovarian cancer, pancreatic cancer, and breast cancer. Our lead product oregovomab, an ovarian cancer treatment, was able to improve PFS by 30months when given with chemotherapy in phase 2. We are currently running the phase 3 study in 16 different countries at 162 sites.

Pipeline

			On-going (진행 중) Planned (준비 중)			
Study ID	NCT no.	Ovarian Cancer (Front Line, 난소암 신규환자)	Preclinical	Phase 1	Phase 2	Phase 3
QPT-ORE-005 (FLORA-5)	NCT04498117	Chemotherapy(Paclitaxel-Carboplatin) + Oregovomab Cohort1 Primary Surgery + Chemo + Oregovomab Cohort2 NACT + Interval Surgery + Chemo + Oregovomab				
Study ID	NCT no.	Ovarian Cancer (Recurrent, 난소암 재발환자)	Preclinical	Phase 1	Phase 2	Phase 3
KM-21 (K-Master)	NCT04938583	Chemotherapy + AVASTIN(Bevacizumab) + Oregovomab				
Orion2 (NCC OV-03)	NCT04620954	Chemotherapy + OPDIVO(Nivolumab) + Oregovomab				
OQP-ORE-004	-	ZEJULA (Niraparib + Oregovomab)				
Study ID	NCT no.	Pancreatic Cancer (췌장암)	Preclinical	Phase 1	Phase 2	Phase 3
N/A	-	Chemotherapy + MAb-AR20.5 (anti-MUC1)				
Study ID	NCT no.	Breast Cancer (유방암)	Preclinical	Phase 1	Phase 2	Phase 3
N/A	-	Ant-Her2/neu IgE Immunotherapy				

Global offices

Office in South Korea

분당 사무소: 경기 용인시 수지구
신수로 767(동천동 분당 수지
유타워 지식산업센터 1707 호)

Pharmaceutical Company

Celcuity



Booth : # 6146

CONTACT

PHONE :

Address : 16305 36th Avenue
North, Minneapolis, MN 55446

WEBSITE :

<https://www.celcuity.com/about/>


About

Celcuity Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumors. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer, is currently enrolling patients.

Pipeline

The PI3K/mTOR pathway has been implicated in breast, prostate, endometrial, ovarian and hematological cancers, among others. We are currently developing our lead drug candidate, gedatolisib, in metastatic breast cancer.

Therapeutic Pipeline: Gedatolisib



Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Celltrion Healthcare



Booth : # 3146

인천광역시 연수구 아카데미로 51 번길 19

CONTACT

PHONE : +82) 0328506400

WEBSITE : www.celltrionhealthcare.com

■ About

Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion through an extensive global network that spans more than 120 different countries, including both developed and emerging markets.



Global offices

Celltrion USA

CelltrionUSA@celltrion.com

Office in South Korea

Pharmaceutical Company

Cogent Biosciences



Booth : # 14177

CONTACT

PHONE :

(617) 945-5576

Address :

275 Wyman Street, 3rd floor
Waltham, MA 02451

investorrelations@cogentbio.com


WEBSITE :

<https://www.cogentbio.com>

■ About

Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezucastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezucastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.

■ Pipeline



Find out more about pipelines at www.cogentbio.com

Global offices

4840 Pearl E Circle
Suite 100
Boulder, CO 80301

Office in South Korea

N/A

Pharmaceutical Company

Coherus BioSciences



Booth : # 2097

CONTACT

PHONE : 800-794-5434

Address : 333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

WEBSITE : <https://www.coherus.com/>

Investors:

Marek Ciszewski, SVP Investor Relations
IR@coherus.com

Media:

Jodi Sievers, VP Corporate Communications
media@coherus.com

About

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus' strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma is currently under review by the FDA. Coherus' earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in combination with toripalimab, CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways. Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, and CIMERLI™ (ranibizumab-eqrn), a biosimilar of Lucentis®, in the U.S., and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023. (TA for marketed products: Oncology, Ophthalmology, Immunology)

Pipeline

Innovative Immuno-Oncology Pipeline								
Candidate	Target	Proposed Indication	Preclinical	Phase 1/2	Pivotal Clinical Trials	BLA Submission	Approved	Marketed*
toripalimab**	PD-1	Nasopharyngeal carcinoma (IL combo with chemo)	████████	████████	████████	████████		
		Nasopharyngeal carcinoma (2L/3L monotherapy)	████████	████████	████████	████████		
CHS-006**	TIGIT	Hepatocellular Carcinoma	████████	████████				
		Non-small Cell Lung Cancer	████████	████████				
		Small Cell Lung Cancer	████████	████████				
		Solid Tumors (All indications in combination with toripalimab)	████████	████████				
CHS-1000	ILT4	Solid Tumors (in combination with toripalimab)	████████					

Find out more about pipelines at <https://www.coherus.com/products-and-pipeline>

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

CRIPR Therapeutics



Booth : # 18170

CONTACT

PHONE : 617-315-4600

Address : 105 West First Street

South Boston, MA 02127

WEBSITE : <http://www.crisprtx.com/>

info@crisprtx.com


bd@crisprtx.com

Employees: 458

About

At CRISPR Therapeutics, we are focused on developing transformative gene-based medicines for serious human disease. The company is rapidly translating specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other disease.

Pipeline



For more information, please visit

<http://www.crisprtx.com/programs/pipeline>

Global offices

Switzerland Office

CRISPR Therapeutics

Baarerstrasse 14

ZUG V8 CH-6300

San Francisco Office

Office in South Korea

N/A

Pharmaceutical Company

CTI BioPharma Corp.



Booth : # 22169

CONTACT

PHONE : +1 206-282-7100

Address : 3101 Western Ave., #800
Seattle WA 98121

WEBSITE :

<https://www.ctibiopharma.com>

Employees: 128

Revenue: \$0.053B

■ About

At CTI, we are resolute in our commitment to deliver new medicines to patients with blood-related cancers who have limited treatment options. With our deep hematology-oncology expertise and sense of urgency, we are motivated to shift the treatment paradigm for blood-related cancers.

By identifying specific patient communities currently underserved by existing therapies and uncovering the scientific factors driving their diseases, we aim to advance the development of therapies that are potentially less toxic and more effective at treating patients.

Marketed product: VONJO(pancritinib)

■ Clinical Trials

TRIAL/STATUS	INDICATION	OVERVIEW
PACIFICA Phase 3 Ongoing	Myelofibrosis with severe thrombocytopenia	The PACIFICA trial is a randomized, controlled phase 3 study of pacritinib versus Physician's Choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet count 50,000/ μ L). Learn more (NCT03165734) .
ALLOGENIC HCT Phase 1/2 Ongoing	Acute Graft Versus Host Disease	This is an investigator-sponsored, single-arm, phase I/II, study of Pacritinib with Sirolimus and Tacrolimus (PAC/SIR/TAC) for the prevention of acute graft versus host disease (GvHD) after matched related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). The study is being conducted at the Mayo Clinic and Moffitt Cancer Center. Learn more (NCT02891603) .
PRE-VENT Phase 2 Complete	Severe COVID-19	The PRE-VENT study was a randomized, double-blind, placebo-controlled multicenter Phase 2 study, comparing pacritinib plus standard of care versus placebo and standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer, to evaluate whether pacritinib can prevent progression to acute respiratory distress syndrome and mechanical ventilation. Learn more (NCT04404361) .

For more information, please visit <https://www.ctibiopharma.com/clinical-trials/>

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

Curis, Inc.



Booth : # 28087

CONTACT

PHONE : (617) 503-6500

Email: info@curis.com

Address : 128 Spring Street

Building C- Suite 500

Lexington, MA 02421

WEBSITE : <https://www.curis.com/>


No. of Employees : 51

Revenue : \$10,649

About

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies.

Pipeline



For more detail, please visit <https://www.curis.com/pipeline/pipeline-overview/>

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

Daiichi-Sankyo



Passion for Innovation. Compassion for Patients.™

Booth : # 10135

CONTACT

PHONE : +81-3-6225-1111.

Email:

ds_corp@daiichisankyo.co.jp

Address : 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8426, Japan

WEBSITE :

<https://www.daiichisankyo.com/>

No. of Employees : 15,348

Revenue : \$500 M

About Daiichi-Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. The company provides innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, the company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, the company creates innovative new and generic medicines, and new methods of drug discovery and delivery.

Pipeline

Phase 1

(JUSEU/Asia) HER2+ BC 2L+ 1L DESTINY-Breast07	(JUSEU/Asia) HER2 low BC chemo naïve/post chemo DESTINY-Breast06	(JP/US/EA/Asia) HER2+ GC combo, 2L+ 1L DESTINY-Gastro03	(EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JUSEU) BC, bladder (pembrolizumab combo)
(JUSEU) BC, NSCLC (pembrolizumab combo)	(JUSEU/Asia) solid tumors (AUS0305 combo) PETRA	(JP/US) NSCLC, TNBC BC1, SCLC, GC, urothelial, hepatogal, prostate, etc. THORON-PanTumor01	(CN) NSCLC, TNBC THORON-PanTumor02	(JP/US/EA/Asia) NSCLC (w/ AGA, pembrolizumab combo) THORON-Lung02
(JP/US/EA) NSCLC (w/ AGA, durvalumab combo) THORON-Lung04	(JP/US/EA/Asia) solid tumors (AUS0305 combo) PETRA	(JP/US/EA/Asia) NSCLC	(JP/US) EGFR mutated NSCLC (osimertinib combo)	(JP/US) HER3+ BC

Phase 2

(JUSEU/Asia) TNBC (durvalumab combo) BEGONA	(CN) HER2+ GC 2L DESTINY-Gastro06	(JP/US/EA) HER2+ or HER2 mutant NSCLC 2L+ DESTINY-Lung01	(JP/US/EA/Asia) HER2 mutant NSCLC 2L+ DESTINY-Lung02	(CN) HER2 mutant NSCLC 2L+ DESTINY-Lung05
(JUSEU/EA) NSCLC (durvalumab combo) 2L+ HUDSON	(JP/US/EA) HER2+ CRC 3L DESTINY-CRC01	(JP/US/EA/Asia) HER2+ CRC 3L DESTINY-CRC02	(JP/US/EA/Asia) HER2 mutant tumor DESTINY-PanTumor01	(JUSEU/EA) HER2 expressing tumor DESTINY-PanTumor02
(JP/US/EA/Asia) endometrial, ovarian, CRC, GC, CHC combo THORON-PanTumor03	(JP/US/EA/Asia) NSCLC (w/ AGA) THORON-Lung05	(JP/US/EA/Asia) TNBC (durvalumab combo) BEGONA	(JP/US/EA/Asia) EGFR mutated NSCLC (osimertinib combo) 2L ONCHARD	(JP/US/EA/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung01

Phase 3

(JP/US/EA/Asia) HER2+ BC 3L DESTINY-Breast08	(JP/US/EA/Asia) HER2+ BC adjuvant*2 DESTINY-Breast05	(JP/US/EA/Asia) HER2 low BC chemo naïve DESTINY-Breast06	(JP/US/EA/Asia) HER2+ BC 1L DESTINY-Breast09	(JP/US/EA/Asia) HER2+ BC neoadjuvant DESTINY-Breast11
(JP/US/EA/Asia) HER2+ GC 2L DESTINY-Gastro04	(JP/US/EA/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04	(JP/US/EA/Asia) NSCLC 22L THORON-Lung01	(JP/US/EA/Asia) non-squamous NSCLC (w/ AGA, pembrolizumab combo) 1L THORON-Lung07	(JP/US/EA/Asia) NSCLC (w/ AGA, pembrolizumab combo) 1L THORON-Lung08
(JP/US/EA/Asia) BC1 2L THORON-Breast01	(JP/US/EA/Asia) TNBC 1L THORON-Breast02	(JP/US/EA/Asia) TNBC (w/ durvalumab combo) adjuvant*3 THORON-Breast03	(JP/US/EA/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02	

Submitted

(CN) HER2+ BC 2L DESTINY-Breast03	(JP/CN) HER2 low BC post chemo DESTINY-Breast04	(JP/EA) HER2 mutant NSCLC 2L+ DESTINY-Lung01/Lung02
-----------------------------------	---	---

Global offices

New York (USA), Munich(Germany), Vancouver(Canada), Sao Paulo(Brazil), etc.

Office in South Korea

East Tower 15th Fl. Mirae Asset Center1, 26 Eulji-ro 5-gil, Jung-gu, SEOUL 04539 KOREA

Phone: +82-2-3453-3300

Pharmaceutical Company

**Day One
Biopharmaceuticals, Inc.**



Booth : #27155

CONTACT

PHONE :
1-650-484-0899

Address :
2000 Sierra Point Parkway, Suite 501
Brisbane, CA 94005

WEBSITE : <https://www.dayonebio.com/>

No. of Employees : 119

Revenue : \$11.5M per year

■ About Day One Biopharmaceuticals, Inc.

Day One is a biopharmaceutical company founded to address a critical unmet need - therapeutic development in pediatric cancers. Day One is committed to developing targeted therapies for patients with life-threatening diseases and redefine what's possible for all people living with cancer, regardless of age, starting from Day One.

■ Pipeline as of April 2023

Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

Indication: Relapsed pLGG
Progress: Phase 2
Clinical Trial: Enrolling (FIREFLY-1) ¹

Indication: Frontline pLGG
Progress: Phase 3
Clinical Trial: (FIREFLY-2)

Indication: RAF-altered solid tumors ^{2*}
Progress: Phase 1
Clinical Trial: Enrolling (FIRELIGHT-1)

Pimasertib MEK1/2 Inhibitor

Indication: MAPK-altered solid tumors ^{3*}
Progress: Phase 1
Clinical Trial: Enrolling (FIRELIGHT-1) ⁴

¹ FIREFLY-1 is a pivotal Phase 2 trial expected to support registration.

² DAY101 adult monotherapy Phase 1 dose escalation and expansion trial previously completed.

³ Pimasertib Phase 1 dose escalation and expansion trial previously completed.

⁴ Trial in combination with DAY101.

* Includes patients ≥ 12 years of age.

Find out more about pipelines at <https://www.dayonebio.com/>

Global offices

Global Headquarter:

Day One Biopharmaceuticals

2000 Sierra Point Parkway, Suite
501 Brisbane, CA 94005

1-650-484-0899

Office in South Korea

N/A

Pharmaceutical Company

Deciphera Pharmaceuticals



Booth : # 20145

CONTACT

PHONE : 781.209.6400

Email: info@deciphera.com

Address : Deciphera
Pharmaceuticals, LLC.

200 Smith Street

Waltham, MA 02451

WEBSITE : <https://www.deciphera.com/>

No. of Employees : 300

Revenue : \$121.9 million

■ About Diciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines.

■ Pipeline

		RESEARCH	IND-ENABLING	PHASE 1	PHASE 1/2	PHASE 3	REGULATORY SUBMISSION	APPROVED
QINLOCK[®] <small>(DCC3116)¹ KIT Inhibitor</small>	GIST 3-4 th Line GIST 2 nd Line KIT Exon 11 + 17/18 (INSGHT Phase 3 Study) ²				Phase 3 Planned for 2H 2023 ¹			
Vimseftinib <small>CST1R Inhibitor</small>	TGCT (MOTION Phase 3 Study) TGCT (Phase 1/2 Study)							
DCC-3116 <small>ULK Inhibitor</small>	+ MEK Inhibitors (Trametinib or Binimetinib) + KRAS ^{G12S} Inhibitor (Sotorasib) + BRAF Inhibitor / EGFR Inhibitor (Encorafenib / Cetuximab) + KIT Inhibitor (Ipilimumab)							
DCC-3084 <small>Pan-RAF Inhibitor</small>	Solid Tumors and Hematologic Malignancies							
DCC-3009 <small>Pan-KIT Inhibitor</small>	GIST							
Additional Programs	GON2 VPS34							

Find out more about pipelines at <https://www.deciphera.com/pipeline>

Global offices

Switzerland: +41 41 562 02 50

Germany: +49 89 83931430

France: +33 9 79 99 86 77

Office in South Korea

N/A

Pharmaceutical Company

Eisai Inc.



Booth : # 14027 and #7018

CONTACT

PHONE : 201.692.1100

Email: esi_oncmedinfo@eisai.com

Address : 200 Metro Blvd, Nutley, NJ

07110 United States

WEBSITE : <https://us.eisai.com/>

No. of Employees : 1,864

Revenue : \$5.3 B (2021)

About Eisai Inc.

As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., the company's passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. The company is a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Its key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases).

Oncology Pipeline

(2) Oncology

Development Code: E7080	Generic Name: lenvatinib	Product Name: Lenvima	In-house
Indications / Drug class: Anticancer agent / kinase inhibitor			Oral
Description: An orally available multiple kinase inhibitor that selectively inhibits kinase activities vascular endothelial growth factor receptors (VEGFR); VEGFR1, VEGFR2 and VEGFR3, and fibroblast growth factor receptors (FGFR); FGFR1, FGFR2, FGFR3 and FGFR4, in addition to pathogenic angiogenesis, tumor growth and cancer progression related receptor tyrosine kinases such as the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. Discovered and developed in-house. As monotherapy indications, approved for use in the treatment of thyroid cancer in over 80 countries including Japan, the United States, China and countries in Europe and in Asia. Approved for use in the treatment of hepatocellular carcinoma (first-line) in over 80 countries including Japan, the United States, China and countries in Europe and in Asia. Also approved for use in the treatment of thymic carcinoma in Japan. As a combination therapy with everolimus, approved for use in the treatment of renal cell carcinoma (second-line) in over 65 countries including the United States, countries in Europe and in Asia. As a combination therapy with pembrolizumab, approved for use in the treatment of renal cell carcinoma in over 40 countries including Japan, the United States, and countries in Europe and in Asia, and approved for use in the treatment of endometrial carcinoma in over 45 countries including Japan, the United States, and countries in Europe and in Asia, including conditional approval. The agent is marketed under the product name Kisplyx only for renal cell carcinoma indication in Europe. Joint development with Merck & Co., Inc., Rahway, NJ, USA, through			
Development Code: E7389	Generic Name: eribulin	Product Name: Halaven	In-house
Indications / Drug class: Anticancer agent / microtubule dynamics inhibitor			Injection
Description: A synthetic analog of halichondrin B derived from the marine sponge <i>Halichondria okadai</i> . Shows an antitumor effect by arresting the cell cycle through inhibition of the growth of microtubules. Approved in over 80 countries including Japan, the United States, China and countries in Europe and in Asia for use in the treatment of breast cancer. Approved in over 80 countries including Japan, the United States and countries in Europe and in Asia for use in the treatment of liposarcoma (soft tissue sarcoma in Japan).			
Monotherapy (Additional Formulation)			
Liposomal formulation	—	JP/EU	PI
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)			
Liposomal formulation	Study 120	JP	PI/II
Development Code: H3B-6545	Indications / Drug class: Anticancer agent / ERα inhibitor		In-house
Description: An orally administered selective estrogen receptor (ER) α covalent antagonist that inhibits ERα wild type / ERα mutant. Expected to show an antitumor effect against ER positive / HER2 negative breast cancers.			Oral
Breast cancer	Study 101	US/EU	PI/II
Breast cancer (in combination with CDK4/6 inhibitor palbociclib)	—	US/EU	PI
Development Code: E7090	Generic Name: tasurgatinib	Product Name: tasurgatinib	In-house
Indications / Drug class: Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor			Oral
Description: An orally administered fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor. Phase II clinical study for unresectable cholangiocarcinoma (one of biliary tract cancers) with FGFR2 gene fusion is ongoing. It has been granted the orphan drug designation with a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare (MHLW) in Japan.			
Cholangiocarcinoma	Study 201	JP/CH	PI
Breast cancer	—	JP	PI

Find out more about pipelines at

<https://www.eisai.com/company/business/research/pdf/epipeline.pdf>

Global offices

Tokyo: +81-3-3817-3700

Office in South Korea

Seoul, Gangnam-gu, Samseong-dong, Bongeunsa-ro 86-gil, 6
빌딩레베상트 10 층

02-3451-5500

Pharmaceutical Company

Elevar Therapeutics



Booth : # 25147

CONTACT

PHONE : 1-801-303-7440 x300

Email:

Address : One Bridge Plaza North, Suite
850, Fort Lee, NJ
07024 U.S.A.

WEBSITE :

<https://elevartherapeutics.com/>

No. of Employees : 65

Revenue : \$2.69 million

■ About Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas.

■ Pipeline

Rivoceranib Pipeline



Find out more about pipelines at

<https://elevartherapeutics.com/rivoceranib-apatinib-elevar/>

Global offices

Salt Lake City
Ireland: 353-1-969-6739

office in South Korea

7F Mayple Tower, Teheran-ro 420,
Gangnam-gu, Seoul 06193
Republic of Korea

Pharmaceutical Company

Eli Lilly and Company



Booth : # 14007

CONTACT

PHONE : +1-317-276-2000

Address : **Lilly Global**

Headquarters

Eli Lilly and Company

Lilly Corporate Center

Indianapolis, IN 46285

WEBSITE : <https://www.lilly.com/>


No. of Employees : 33,625

Revenue : \$28.54 B

■ About Eli Lilly and Company

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Its approach centers on creating new medicines that work in early clinical development and will matter to patients.

■ Oncology Pipeline



For more detail, please visit <https://www.lilly.com/discovery/clinical-development-pipeline>

Global offices

USA, China, Europe, Hong Kong, India, Italy, Japan, Mexico, Sweden, United Kingdom, etc.

Office in South Korea

02-3459-2600
서울특별시 중구 후암로 98 4 층
(우) 04637

Pharmaceutical Company

Exelixis, Inc.



Booth : # 21081 and #14035

CONTACT

PHONE : (650) 837-7000

Email: N/A

Address :

1851 Harbor Bay Parkway

Alameda, CA 94502

WEBSITE : <https://www.exelixis.com/>


No. of Employees : 954

Revenue : \$1.4 billion

About Exelixis, Inc.

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need.

Pipeline



Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Fresenius Kabi USA, LLC



Booth : #27169

CONTACT

PHONE :
+41223076100

Address :
Fresenius Kabi USA
Three Corporate Drive
Lake Zurich, Illinois 60047

WEBSITE : <https://www.fresenius-kabi.com/us/>


No. of Employees : >2500

Revenue : \$800.0M (2022)

■ About. Fresenius Kabi USA, LLC

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. We offer the most comprehensive portfolio of generic injectable and infused oncology medicines in the United States, and we have an exciting pipeline of medicines in development, including a range of biosimilars. Fresenius Kabi has a rich history of more than 100 years of experience and is known for award-winning customer service and dedication to supplying hospitals, long-term care facilities, alternate-care sites and clinics.

■ Pipeline as of April 2023



Find out more about pipelines at <https://www.fresenius-kabi.com/us/>

Global offices

Reginal headquarters:
Massachusetts (United States)
Hong Kong (China), Rio de Janeiro
(Brazil)

Office in South Korea

Fresenius Kabi Korea
8, 9th Floor, 69, Baekjegobun-ro,
Songpa-gu, Seoul, Republic of
Korea
02)3484-0900

Pharmaceutical Company

Galera Therapeutics, Inc.



Booth : #6126

CONTACT

PHONE :

610-725-1500

Address :

2 West Liberty Boulevard, Suite 100
Malvern, PA 19355

WEBSITE : <https://www.galeratx.com/>

No. of Employees : 119

Revenue : \$11.5M per year

■ About Galera Therapeutics, Inc.

Galera Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy.

■ Pipeline as of April 2023

PATIENT POPULATION	THERAPEUTIC TARGET	PHASE 1	PHASE 2	PHASE 3	TRIAL STATUS
Head & Neck Cancer	Radiation-induced severe oral mucositis	ROMAN: Avasopasem vs placebo			NDA Submitted to FDA
		EUSOM: Avasopasem			Completed
Lung Cancer	Radiation-induced esophagitis	AESOP: Avasopasem			Completed
		GRECO-1: Rucosopasem vs placebo			Recruiting
Pancreatic Cancer	Increased SBRT efficacy	GRECO-2: Rucosopasem vs placebo			Recruiting

SBRT=stereotactic body radiation therapy. NDA=New Drug Application. FDA=U.S. Food and Drug Administration.

Find out more about pipelines at <https://www.galeratx.com/>

Global offices	Office in South Korea
N/A	N/A

Pharmaceutical Company

Genentech



BOOTH : # 10005

CONTACT

PHONE : (844) 287-3783 (CU-REQUEST)

Email: <https://www.gene.com/contact-us/email-us>

Address :

1 Dna Way Mailstop 258A, South San Francisco, California, 94080, United State

WEBSITE :

<http://www.GenentechOncology.com>

No. of Employees : 13,539


Revenue : \$26.4 Billion (2020)

• About Genentech

Every person with cancer has their own story; and each unique story shapes ours, fueling our dedication to pursue science and bring the best care to each individual. Our power is in discovering innovative medicines and personalizing cancer care. For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. Building on our legacy as the pioneer in cancer innovation, Genentech, a proud member of the Roche Group, has the opportunity to revolutionize new approaches to cancer care.

• Pipeline as of April 2023

Displaying 26 Molecules



MOLECULE	PHASE
Atezolizumab Solid tumors Metastatic melanoma	▼ ■ ■
Autogene cevumeran Solid Tumors Advanced melanoma	▼ ■ ■
Belvarafenib Solid tumors	▼ ■
Cevostamab Multiple myeloma	▼ ■
Cobimetinib Solid tumors Metastatic melanoma	▼ ■ ■

Find out more about pipelines at <https://www.gene.com/medical-professionals/pipeline?phase=1,2,3&category=neuroscience>

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

Genmab



Booth : # 2135, #CF42, and #CF43

CONTACT

PHONE : +1 609 430 2481

Email: info@genmab.com

Address :

777 Scudders Mill Road
Plainsboro, NJ 08536
USA

WEBSITE : <http://www.genmab.com>


No. of Employees : 1,660

Revenue : \$2.067 Billion (2022)

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Pipeline



More : <https://www.genmab.com/pipeline/#page-products>

Global offices

Denmark, The Netherlands, Japan

office in South Korea

N/A

Pharmaceutical Company

Geron, Inc.



Booth : #27146

CONTACT

PHONE :
(650) 473-7700

Address :
919 E. Hillsdale Blvd, Suite 250
Foster City, CA 94404

WEBSITE : <https://www.geron.com/>


No. of Employees : 82

Revenue : \$0.59 M (2022)

■ About Geron, Inc.

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of innovative therapeutics for hematologic malignancies - cancers that affect blood and bone marrow. Founded in 1990, Geron has office locations in Foster City, California and Parsippany, New Jersey. A United Kingdom subsidiary was established in late 2021.

■ Pipeline as of April 2023



Find out more about pipelines at <https://www.geron.com/>

Global offices

Corporate Headquarters:
919 E. Hillsdale Blvd, Suite 250
Foster City, CA 94404
(650) 473-7700

New Jersey Office:
3 Sylvan Way, Suite 202
Parsippany, NJ 07054

Office in South Korea

N/A

Pharmaceutical Company

Gilead and Kite Oncology



Booth : # 6097

CONTACT

PHONE : +1 650 574 3000

Email: public_affairs@kitepharma.com

Address :

333 Lakeside Drive

Foster City, CA 94404

WEBSITE : <https://www.gilead.com/>

No. of Employees : 11,800 (Gilead Sciences)

Revenue : \$27.3 billion (2022)

■ About Gilead and Kite Oncology

Gilead and Kite Oncology are creating the future of oncology to help bring more life to people with cancer. At Gilead, we are focused on delivering transformational science, maximizing speed to the patient and being a partner of choice. As the cell therapy leader, Kite's singular focus is to treat and potentially cure cancer by harnessing the power of a patient's own immune system. We are focused on delivering therapies for some of the most difficult-to-treat cancers. Together, Gilead and Kite Oncology provide hope for many types of tumors where there remains high unmet need.

■ Oncology Pipeline

Oncology

Breast

Sacituzumab govitecan-hziy (ASCENT-03)
1L metastatic triple-negative breast cancer (PD-L1-)

PHASE 3

Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-04)¹
1L metastatic triple-negative breast cancer (PD-L1+)

PHASE 3

Sacituzumab govitecan-hziy + pembrolizumab (ASCENT-05)
Adjuvant triple-negative breast cancer

PHASE 3

Magrolimab + chemotherapy/SG combinations
Triple-negative breast cancer

PHASE 2

Find out more about pipelines at <https://www.gilead.com/science-and-medicine/pipeline>

Global offices

North America, Asia, Middle East,
Europe

Office in South Korea

Gilead Sciences Korea Ltd.

서울특별시 중구 을지로 5 길 26,
04539

Pharmaceutical Company

Greenwich LifeSciences



**Greenwich
LifeSciences**

Booth : #8163

CONTACT

PHONE :

(832) 819-3232

Address :

3992 Bluebonnet Dr Bldg 14, Stafford,
Texas, 77477, United States

WEBSITE :

<https://greenwichlifesciences.com/>

No. of Employees : <25

Revenue : <\$5 Million

■ About Greenwich LifeSciences


Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived from the HER2/neu protein. In a Phase IIb clinical trial in the HER2/neu positive adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up. For the 146 patients who have been treated with GP2 immunotherapy to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy.

■ Products

GP2 Product:

Following breast cancer surgery, a HER2/neu positive patient receives trastuzumab (Genentech/Roche's Herceptin, a monoclonal antibody treatment that targets the HER2/neu protein) in the first year and then hopes that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years. Our immunotherapy, GP2, may be synergistic with Herceptin.

GP2 is a nine amino acid transmembrane peptide of the HER2/neu protein. HER2/neu is a cell surface receptor protein that is expressed in 75% of breast cancer in addition to a variety of other common cancers. Following GP2 immunotherapy, CD8+ cytotoxic T lymphocytes ("CTLs") recognize and destroy HER2/neu-expressing cancer cells. GP2 is administered in combination with GM-CSF, an FDA-approved immunoadjuvant, which stimulates the proliferation of antigen presenting cells.



Flamingo-01:



The Phase III clinical trial, Flamingo-01, has commenced.



Flamingo-01 has a planned interim analysis, using a similar treatment regime as the completed Phase IIb clinical trial.

The primary objective of Flamingo-01 is to assess the safety and efficacy of GP2 compared to placebo in HLA-A*02 positive and HER2/neu positive breast cancer patients who have a high risk of disease recurrence (stage I, II, or III at presentation with residual disease at surgery; or, stage III at presentation with pathologic complete response at surgery) and have completed both neoadjuvant and postoperative, adjuvant trastuzumab-based standard of care therapy.

Find out more about pipelines at <https://greenwichlifesciences.com/>

Global offices

N/A

Office in South Korea

N/A

Pharmaceutical Company

GSK



About GSK

GSK is committed to maximising patient survival through transformational medicines. GSK's oncology pipeline is focused on immuno-oncology, tumour cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, and antibody-drug conjugates, either alone or in combination.

Oncology pipeline

Pipeline updated 01 February 2023

⚠ Additional indication ⚡ Immuno-modulator

<input type="checkbox"/> View all therapeutic areas	Compound number / Generic name / Brand name	Indication	Phase	Mode of action / Vaccine type
<input type="checkbox"/> Infectious Diseases	GSK3070785 † mometinib	myelofibrosis	Registration	JAK1, JAK2 and ACVR1 inhibitor
<input type="checkbox"/> HIV	GSK2857916 † belantamab mafodotin Blenrep	2L+ multiple myeloma combination with Pomalyst and dexamethasone	Phase III	ADC targeting B-cell maturation antigen
<input type="checkbox"/> Immunology/ Respiratory	GSK2857916 † belantamab mafodotin Blenrep	2L+ multiple myeloma combination with Velcade and dexamethasone	Phase III	ADC targeting B-cell maturation antigen
<input checked="" type="checkbox"/> Oncology	GSK4069889 (TSR-022) † cobolimab	Non-small cell lung cancer combination with Jemperi (dostarlimab) and docetaxel	Phase III	Anti-T-cell immunoglobulin and mucin domain-3 (TIM-3) antibody
<input type="checkbox"/> Opportunity Driven	GSK3985771 † niraparib Zejula	1L maintenance ovarian cancer combination with Jemperi (dostarlimab)	Phase III	Poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor
	GSK3985771 † niraparib Zejula	1L maintenance non-small cell lung cancer combination with pembrolizumab	Phase III	Poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor

Find More : <https://www.gsk.com/en-gb/innovation/pipeline/>

Booth : #18063

CONTACT

PHONE : +44 20 8047 5000

Email: gsk.korea@gsk.com

Address :

980 Great West Road

Brentford Middlesex TW8 9GS

United Kingdom

WEBSITE : <http://www.gsk.com>

No. of Employees : 69,400

Revenue : \$36 B (2022)

Global offices

United Kingdom, United States,
Singapore

Hanmi Office in South Korea

LS Yongsan Tower, 9th Floor

Hangang 191, Yongsan-gu

Seoul

Tel: +82 (080) 901 4100

Pharmaceutical Company

Hanmi Pharmaceutical



Booth : # 28169

CONTACT

Email :

Address :

14, Wiryeseong-daero, Songpa-gu,
Seoul, Korea

WEBSITE :

<https://www.hanmipharm.com/>

No. of Employees : 2,344

Revenue : \$1.05 Billion (2022)

■ About Hanmi Pharmaceutical

Hanmi recognized as the No.1 R&D investing company in Korea, developing next generation Platform Technologies & new drugs on the fields of oncology, metabolic disorders and rare diseases. Hanmi has worked closely with global partners on various co-developments and collaborations. We are continuing to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.

■ Areas of focus: Oncology, CVRM/Fibrosis, Rare Disease

■ Oncology pipeline as of April 2023

	Preclinical	Phase 1	Phase 2a	Phase 2b	Phase 3/Approved
Oncology	HM99462 (SOSI) Solid tumors	HM97662 (EZH2) Solid tumors, Hematology malignancies	FLX475 (CCR4) Gastric cancer MSD RAPT		ROLVEDON™/ROLONTIS® (eflapragrastim) Chemo-induced neutropenia SPECTRUM
	HM16390 (AP5L-2 analog) Solid tumors	ROLVEDON™/ROLONTIS® (eflapragrastim) Neutropenia, same-day dosing SPECTRUM	poseltinib (BTK) B-cell lymphoma		ORAXOL® (encequidar + paclitaxel) Advanced breast cancer Astell
	BH3120 (PD-L1/4-1BB B5Ab) Solid tumors	belvarafenib (pan-RAF) Solid tumors (melanoma) Genentech	belvarafenib (pan-RAF) BRAF mutant/fusion solid tumor Genentech		posiotinib (pan-HER) NSCLC (exon 20 ins. mut.) SPECTRUM
		BH2950 (PD-1/HER2 B5Ab) Solid tumors Innovent			
		tuspentinib (MK) Acute myeloid leukemia APTIDE			

Find out more about pipelines at

<https://www.hanmipharm.com/ehanmi/handler/Home-Start>

Global offices	Hanmi Office in South Korea
N/A	Phone: +82-2-410-9114 Address: (ZIP : 05545) 14, Wiryeseong-daero, Songpa-gu, Seoul, Korea Fax: +82-2-410-9259

Pharmaceutical Company

Helsinn Healthcare



Booth : # 26174

CONTACT

PHONE : +41 91 985 21 21

Email: info-HHC@helsinn.com

Address :

Via Pian Scairolo 9

6912 Pazzallo-Lugano

WEBSITE : <http://www.helsinn.com>

No. of Employees : 680

Revenue : \$125 Million

■ About Helsinn Healthcare

Helsinn is a global biopharma company focused on addressing unmet needs in cancer. It has a commercial portfolio of cancer therapeutic and supportive care products underpinning the business as it progresses the research and development with an innovative pipeline of highly innovative oncology assets, building its fully integrated targeted therapies (Helsinn's FITT strategy).

Helsinn is guided by core values of respect, integrity and quality and the Group plays an active role in promoting social transformation in favour of people and the environment.

■ Oncology Pipeline

Cancer Therapeutics ▾

Vepafestininib¹



Cancer Supportive Care ▾

Fosnetupitant - Palonosetron



Fosnetupitant - Palonosetron IV



Find More : <https://helsinn.com/our-science/pipeline/>

Global offices

Switzerland, Ireland, United States

China

Helsinn Office in South Korea

N/A

Pharmaceutical Company

ImaginAb, Inc.



Booth : # 28107

CONTACT

Email : info@imaginab.com

Address :

ImaginAb, Inc. U.S.

423 Hindry Ave. Suite D

Inglewood,

CA 90301

WEBSITE : <https://imaginab.com/>

No. of Employees : < 25 employees

Revenue : < \$5 M

About ImaginAb, Inc.

ImaginAb is a clinical stage and revenue-generating biotech company, focused on developing next generation imaging and therapeutic radiopharmaceuticals (RPT) based on our proprietary Minibody and Cys-diabody platform. We have a clearly defined purpose and growth strategy, which will see us working closely with our research and commercial partners to transform patient care, and help people live better and healthier lives.

Pipeline

PET Imaging					
Indication	Preclinical	IND	Phase 1	Phase 2	Phase 3
PET imaging of CD8 Cells in Oncology (89Zr-Df-Cremirimab)					
PET imaging CD8 T-cells in Inclusion Body Myositis (89Zr-Df-Cremirimab)					
PET Imaging CD4 T-cells trafficking in Oncology and Autoimmune diseases (89Zr-Df-IAB41M2C)					

Radiopharmaceutical Therapy (RPT)					
Program	Indication	Discovery	Lead Selection	IND Enabling Studies	Clinical Studies
IAB2MA	RPT Prostate Cancer				
IAB56	RPT Solid Tumors				
IAB57	RPT Small-Cell Lung Cancer				
IAB58	RPT Solid Tumors				
IAB59	RPT Ovarian Cancer				

Optical Imaging					
Indication	Preclinical	IND	Phase 1	Phase 2	Phase 3
PSMA optical imaging: Prostate Cancer (IR800-IAB2MA)					
PSMA optical imaging: Renal Cancer (IR800-IAB2MA)					

Find out more about pipelines at <https://imaginab.com/about/development-pipeline>

Global Offices

US Address: 423 Hindry Ave. Suite D
Inglewood, CA 90301

UK & EU Address: Lily House
Room 11 Bracknell Berks RG12 2SJ
UK

ImaginAb office in South Korea

N/A

Pharmaceutical Company

Immunity Bio



Booth : # 26097

CONTACT

Email : info@ImmunityBio.com

Address :

Culver City, CA

WEBSITE :

<https://www.immunitybio.com/>

No. of Employees : 688 employees

Revenue : \$0.24 M

About Immunity Bio

ImmunityBio, Inc. develops next-generation cancer therapies and vaccines that complement and amplify the immune system. Our broad, proprietary immunotherapy, NK cell therapy, and vaccine platforms are designed to attack cancer by activating both the innate and adaptive immune system in an orchestrated manner to outsmart the disease and establish "immunological memory" that confers long-term benefit for the patient.

Pipeline

SOLID TUMORS						
DISEASE	TRIANGLE OFFENSE	TRIAL SITES/COLLABORATORS	PRE-IND	PHASE 1	PHASE 2	PHASE 3
Bladder Cancer: QUILT-3.032 BCG Unresponsive NMIBC Carcinoma In-Situ (Cohort A)	Anktiva + BCG Details	32 study locations (see clinicaltrials.gov for details)				
Bladder Cancer: QUILT-3.032 BCG Unresponsive NMIBC Papillary (Cohort B)	Anktiva + BCG Details	32 study locations (see clinicaltrials.gov for details)				
Bladder Cancer: QUILT-2.005 BCG Naive NMIBC	Anktiva + BCG Details	24 study locations (see clinicaltrials.gov for details)				
Lung Cancer: QUILT-2.023 1L Squamous & Non-Squamous Non-Small Cell - Lung Cancer Checkpoint Alone	Anktiva + Keytruda (Pembrolizumab) Details	31 study locations (see clinicaltrials.gov for details)				
Pancreatic Cancer: QUILT-88 3L Metastatic Pancreatic Cancer (Cohort C)	Anktiva + Aldox + PD-L1 t-haNK Details	Hoag Memorial Presbyterian Hospital (Newport Beach, CA); Avera Cancer Institute (Sioux Falls, SD); Astera Cancer Care (East Brunswick, NJ)				
Pancreatic Cancer: QUILT-88 2L Metastatic Pancreatic Cancer (Cohort B)	Anktiva + Aldox + PD-L1 t-haNK Details	Hoag Memorial Presbyterian Hospital (Newport Beach, CA); Avera Cancer Institute (Sioux Falls, SD); Astera Cancer Care (East Brunswick, NJ)				

Find out more about platform at <https://immunitybio.com/pipeline/>

Global Offices

Global Headquarters

Culver City, CA

9920 Jefferson Blvd.

Culver City, CA 90232

Immunity Bio Office in South Korea

N/A

Pharmaceutical Company

Immunocore

IMMUNOCORE

Booth : #2074

CONTACT

PHONE :

+44 (0)1235 438600

Address :

Immunocore Limited
92 Park Drive, Milton Park, Abingdon,
Oxon, OX14 4RY, UK

WEBSITE :

<https://www.immunocore.com/>

No. of Employees : 324

Revenue : \$40.4 million

■ About Immunocore

Immunocore is a commercial-stage biotechnology company with a mission to radically improve outcomes for patients living with cancer, infectious diseases, and autoimmune conditions by pioneering and delivering transformative medicines. In 2022 we launched the world's first T cell receptor (TCR) therapy, ushering in a new era of cancer therapeutics. By unlocking >90% of cancer targets, our modular and off-the-shelf ImmTAC technology is designed to harness the natural immune system's power to fight multiple cancers and help address unmet needs.

■ Pipeline as of April 2023

Candidate	Target (HLA type)	Indication	IND-enabling	Phase 1	Phase 2	Phase 3	Approved
KIMMTRAK Tebentafusp	gp100 (A02)	Uveal melanoma					
		Advanced melanoma					
		Multiple solid tumors	Monotherapy dose exploration				
		Multiple solid tumors	Combinations with standards of care				
IMC-F106C	PRAME (A02)	2L+ cutaneous melanoma					
		PRR Ovarian*					
		Advanced endometrial					
		2L+ NSCLC					
IMC-P115C	PRAME-HLE (A02)	Multiple solid tumors					
IMC-T119C	PRAME (A24)	Multiple solid tumors					
IMC-R117C	PIWIL1 (A02)	Colorectal, gastric, pancreatic					
IMC-M113V ¹	Gag (A02)	Human Immunodeficiency Virus (HIV)					
IMC-I109V	Envelope (A02)	Hepatitis B Virus (HBV)					

Find out more about pipelines at <https://www.immunocore.com/>

Global offices

Pennsylvania, US

Maryland, US

Dublin, Ireland

Immunocore Office in South

Korea

N/A

Pharmaceutical Company

ImmunoGen, Inc.



Booth : #15169

CONTACT

Email : info@immunogen.com

Address :

ImmunoGen, Inc.

830 Winter Street

Waltham, MA 02451-1477

WEBSITE : <http://www.immunogen.com/>


No. of Employees : 75 employees

Revenue : \$15.4 M (2022)

About ImmunoGen, Inc.

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to "target a better now." The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.

Pipeline



Find out more about platform at <https://www.immunogen.com/what-we-do/our-pipeline/>

Global Offices

Corporate Headquarters

830 Winter Street

Waltham, MA 02451-1477

Phone: 781-895-0600

ImmunoGen Office in South

Korea

N/A

Pharmaceutical Company

Incyte



Booth : # 19043

CONTACT

Email : media@incyte.com

Address :

Wilmington, DE

WEBSITE : <http://www.incyte.com>

No. of Employees : 2,094

Revenue : \$3.4 B (2022)

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Portfolio

- **20 Molecular Targets, 25 Clinical Candidates, 8 Approved Products**

General Hematology/Oncology

Close ^

Product	Clinical Proof of Concept	Pivotal	Approved
Pemazyre® (pemigatinib) FGFR1/2/3 2L+ cholangiocarcinoma ⁴ , MLNs with <i>FGFR</i> rearrangement ^{2/4}			
Monjuvi® (tafasitamab-cxix) ⁵ Minjuvi® (tafasitamab) ⁵ CD19 r/r DLBCL ^{2/5/7}			
Iclusig® (ponatinib) ⁸ BCR-ABL Chronic myeloid leukemia ⁶ , Ph+ ALL ⁶			
Zynjyz TM (retifanlimab-divr) ⁹ PD-1 (mAb) Merkel cell carcinoma ²			
pemigatinib FGFR1/2/3 1L cholangiocarcinoma			
pemigatinib FGFR1/2/3 NSCLC, glioblastoma			

<https://www.incyte.com/what-we-do/pharmaceutical-portfolio>

Global Offices

- North America, Asia, Europe

Incyte office in South Korea

N/A

Pharmaceutical Company

Iovance Biotherapeutics



Booth : # 8155

CONTACT

Email : info@iovance.com

Address :

South San Carlos, CA

WEBSITE : <https://www.iovance.com>

Tel: 650-260-7120

No. of Employees : 319 employees

Revenue : \$105.88M

About Iovance Biotherapeutics

Iovance Biotherapeutics is investigating Tumor Infiltrating Lymphocyte (TIL) cell therapy in patients with solid tumors and blood cancers. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient.

Clinical Pipeline

TIL						
Product Candidate	Indication(s)	IND-Enabling	Phase 1	Phase 2	Pivotal	
Lifileucel/LN-144	Melanoma (post-anti-PD-1)	C-144-01 Study, Cohorts 2 & 4		FDA RMAT designation		View trial →
Lifileucel	Cervical cancer (post-chemo; post-chemo & post-anti-PD-1)	C-145-04 Study, Cohorts 1 & 2		FDA BTB		View trial →
LN-145	NSCLC (2L post-chemo & post-anti-PD-1)	IOV-LUN-202 Study, Cohorts 1 & 2				View trial →
LN-145	NSCLC (2-4L incl. post-anti-PD-1)	IOV-COM-202 Study, Cohort 3B				View trial →
LN-145	HNSCC (post-anti-PD-1)	C-145-03 Study, Cohort 2				View trial →
TIL Combinations						
Product Candidate	Indication(s)	IND-Enabling	Phase 1	Phase 2	Pivotal	
Lifileucel + pembro	Melanoma (anti-PD-1 naïve)	IOV-COM-202 Study, Cohort 1A				View trial →
Lifileucel + pembro	Cervical cancer (1L, chemo & anti-PD-1 naïve)	C-145-04 Study, Cohort 3				View trial →
LN-145 + pembro	NSCLC (anti-PD-1 naïve)	IOV-COM-202 Study, Cohort 3A				View trial →
LN-145 + ipi/nivo	NSCLC (post-anti-PD-1)	IOV-COM-202 Study, Cohort 3C				View trial →
LN-145 + pembro	HNSCC (anti-PD-1 naïve)	IOV-COM-202 Study, Cohort 2A				View trial →
PD-1 Selected TIL						
Product Candidate	Indication(s)	IND-Enabling	Phase 1	Phase 2	Pivotal	
LN-145-S1	Melanoma (post-anti-PD-1)	IOV-COM-202 Study, Cohort 1B				View trial →
LN-145-S1	HNSCC (post-anti-PD-1)	C-145-03 Study, Cohort 4				View trial →
Third Generation (Gen 3) TIL: 16-day manufacturing						
Product Candidate	Indication(s)	IND-Enabling	Phase 1	Phase 2	Pivotal	
LN-145 Gen 3 + core biopsy	NSCLC (2L post-chemo & post-anti-PD-1)	IOV-LUN-202 Study, Cohort 3				View trial →
LN-145 Gen 3	Melanoma (post-anti-PD-1)	IOV-COM-202 Study, Cohort 1C				View trial →
LN-145 Gen 3	HNSCC (post-anti-PD-1)	C-145-03 Study, Cohort 3				View trial →
PBL Therapy						
Product Candidate	Indication(s)	IND-Enabling	Phase 1	Phase 2	Pivotal	
IOV-2001	CLL/SLL (post-BTK)	IOV-CLL-01 Study				View trial →

Find out more about solutions at <https://www.iovance.com/clinical-pipeline/>

Global Offices

North America, Asia, Europe

Office in South Korea

N/A

Pharmaceutical Company

Ipsen Biopharmaceuticals, Inc



Booth : # 2089 and #2063

CONTACT

Address :

One Main Street, Cambridge, MA

WEBSITE : <https://www.ipsen.com/us/>

No. of Employees : 5,700

Revenue : \$3.4B

■ About Ipsen Biopharmaceuticals, Inc.

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing medicines in three key therapeutic areas – Oncology, Rare Disease and Neuroscience. We are dedicated to providing hope for patients whose lives are challenged by unmet medical needs. Our North American operations are located in Cambridge, Massachusetts, one of the company's three global hubs. For more information please visit www.ipsenus.com.

- **Approved Products:** TAZVERIK (tablets), Onivyde (irinotecan liposome injection), Somatuline Depot (lanreotide, injection), Dysport (abobotulinumtoxinA), Increlex (mecasermin, injection 10mg)

■ Pipelines as of Feb 2023

Phase I	Phase II	Phase III	Registration
IPN60210 R/R multiple myeloma and R/R DLBCL	TAZVERIK (various combinations) R/R hematologic malignancies	CABOMETYX + ATEZOLIZUMAB 2L mCRPC	PALOVAROTENE FOP
IPN10200 Longer-acting neurotoxin Tx	TAZVERIK (+ hormone therapy) mCRPC	ONIVYDE + 5-FU/LV + OXALIPLATIN 1L PDAC	
	FIDRISERTIB FOP	TAZVERIK + R ² 2L FL	
	ELAFIBRANOR PSC	ELAFIBRANOR 2L PBC	
	MESDOPETAM PD-L1iD		
	IPN10200 Longer-acting neurotoxin Tx		

■ Oncology
■ Rare disease
■ Neuroscience

Find out more about solutions at <https://www.ipsen.com/our-science/rd/>

Global Offices	Office in South Korea
North American Commercial Headquarters : Cambridge, MA Global R&D and External Innovation & Partnering : Cambridge, MA	N/A

Pharmaceutical Company

Jazz Pharmaceutical, Inc.



Booth : # 26081

CONTACT

Address :

Palo Alto, CA

WEBSITE :

<https://www.jazzpharma.com/>

No. of Employees : 1600

Revenue : \$3.7 B (2022)

About Jazz Pharmaceutical

Jazz Pharmaceuticals Inc is a specialty biopharmaceutical company. The Company is focused on identifying, developing and commercializing products that address unmet medical needs. Jazz Pharmaceutical has a diverse portfolio of products in the areas of narcolepsy, severe chronic pain, psychiatry and women's health.

Pipelines as of April 2023

PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	REGULATORY
Undisclosed targets Neuroscience	JZP324 ² Oxybate extended-release formulation	Suvectamamide (JZP385) Essential tremor	Zanidatamab ² HER2-targeted bispecific antibody 1L zani + chemo + tislelizumab for GEA ⁶ (Pivotal trial)	JZP458 (Rylaze) ⁶ (recombinant <i>Erwinia asparaginase</i>) ALL/ABL
CombiPlex Exploratory activities	JZP441 (DSP-0187) ² Orexin-2 receptor agonist	Suvectamamide (JZP385) Parkinson's Disease Tremor		
Undisclosed target Ras/Raf/MEK/ERK pathway ¹	JZP815 Pan-Raf inhibitor program Raf & Ras mutant tumors	JZP150 ⁵ PTSD	Lurbinectedin ¹ 1L treatment SCLC in combination with Tecentriq [®] (atezolizumab)	
Exosome targets (Up to 3 targets) ¹ Hematological malignancies/solid tumors	Zanidatamab ² HER2-targeted bispecific antibody Breast cancer	Zanidatamab ² HER2-targeted bispecific antibody • 2L zani monotherapy for BTC ² (Pivotal trial) • Additional trials ongoing in BTC, GEA and CRC • Multiple trials ongoing in breast cancer	JZP351 • AML or HR-MDS >60 yrs (AML18) ⁷ • Newly diagnosed adults with standard- and HR-AML (AML5G) ⁷ • Newly diagnosed <22 yrs with AML (COG) ⁷	
JZP838 (WTX-513) ² Conditionally-activated IFNα	JZP541 (Long-acting <i>Erwinia asparaginase</i>) Solid tumors			
Undisclosed targets Oncology	JZP351 (Vyxeos) Low Intensity Dosing for higher risk MDS ⁴	Lurbinectedin (Zepzelca) Basket trial: advanced urothelial cancer, large cell neuroendocrine tumor of the lung, HRD+ cancers	Cannabidiol (Epidiolex) EMAS	
Undisclosed targets Cannabinoids	JZP351 + other approved therapies • R/R AML or HMA • Failure MDS ⁴ • First-line, fit AML (Phase 1b) • Low Intensity Therapy for first-line, unfit AML (Phase 1b)	JZP351 • HR-MDS (EMSCO) ⁷ • Newly diagnosed older adults with HR-AML ⁷	Cannabidiol (Epidiolex) LGS, DS, TSC in Japan	
	Additional Cannabinoids Neonatal hypoxic-ischemic encephalopathy	JZP351 + venetoclax de novo or R/R AML ⁴		
	Additional Cannabinoids Neuropsychiatry targets	JZP541 Irritability associated with autism spectrum disorders		
		Additional Cannabinoids Autism spectrum disorders		

Neuroscience Oncology Cannabinoids ¹Partnership collaboration; ²Recently acquired; ³Planned;

Find out more about solutions at <https://www.jazzpharma.com/science/pipeline/>

Global Offices

Dublin, Ireland/Oxford, England/
Lyon, France/ Munich, Germany/
Palo Alto, CA/ Philadelphia, PA/
Villa Guardia, Italy

Office in Korea

N/A

Pharmaceutical Company

Karyopharm Therapeutics Inc.



Booth : # 18152

CONTACT

Address :

Newton, MA

Tel: +1 (888) 209-9326

Email:

medicalinformation@karyopharm.com

WEBSITE :

<https://www.karyopharm.com>

No. of Employees : 385 employees

Revenue : \$157.1 M (2022)

■ About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.

■ Approved Products

- XPOVIO (selinexor)

■ Pipelines

SELINEXOR

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
w/R-GDP	DLBCL (R/R)	XPORT-DLBCL-030				
monotherapy	Endometrial Cancer (maintenance)	SIENDO				
monotherapy	Endometrial cancer (maintenance; p53 wild-type)					
w/pomalidomide + dexamethasone	Multiple myeloma (2L+)	XPORT-MM-031				
w/standard approved therapies	Multiple myeloma (relapsed/refractory)	STOMP				
monotherapy	Myelofibrosis (previously treated)	XPORT-MF-035				
w/ ruxolitinib	Myelofibrosis (treatment naive)	XPORT-MF-034				

ELTANEXOR

Regimen	Indication	Study Name	Early Stage	Mid Stage	Late Stage	Commercial
monotherapy	Myelodysplastic syndromes (refractory)	KCP-8602-801				
+ hypomethylating agents	Myelodysplastic syndromes (newly diagnosed)	KCP-8602-801				

— Hematologic Cancer
 — Solid Tumor Cancer
 - - - - - Coming Soon

Find out more about R&D at <https://www.karyopharm.com/pipeline/>

Global Offices

Newton (HQ), Providence RI,
München Germany, Giv'atayim.
Israel

Office in Korea

N/A

Pharmaceutical Company

Kinnate Biopharma

KINNATE
B I O P H A R M A

Booth : #20170

CONTACT

PHONE :
858.299.4699

Address :
12830 El Camino Real, Suite 150
San Diego, CA 92130

WEBSITE : <https://www.kinnate.com/>

No. of Employees : 84

Revenue : \$12.9 M (2022)

■ About Kinnate Biopharma

Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate's lead programs include candidates in development for cancers that are driven by specific oncogenic alterations in kinase genes including BRAF Class II and Class III, NRAS, and FGFR2 and FGFR3. Kinnate's mission is to expand the reach of targeted therapeutics by developing products that are designed to address significant unmet need.

■ Pipeline as of April 2023

A Focused Pipeline

We have developed a proprietary portfolio of small molecule candidates targeting validated drivers of cancer.

TARGET, PROGRAMS	INDICATIONS	DISCOVERY	IND-ENABLING	PHASE 1A	PHASE 1B	PHASE 2/3
Exarafenib Monotherapy Pan-RAF	BRAF-Driven Advanced Adult Solid Tumors					
Exarafenib Combination Pan-RAF	Advanced NRAS Mutant Melanoma					
KIN-3248 FGFR2/3- Driven	Naïve + Pre-treated FGFR2/3 Driven Advanced Adult Solid Tumors					
KIN-7136 Brain Penetrant MEK	MAPK-Driven Advanced Adult Solid Tumors					
KIN-8741 c-MET, Covers Acquired Resistance	c-Met-Driven Advanced Adult Solid Tumors					
KIN004 CDK12	Adult Solid Tumors					

Find out more about pipelines at <https://www.kinnate.com/>

Global offices

San Francisco Office

Office in South Korea

N/A

Pharmaceutical Company

LABORATORIO ELEA PHOENIX S.A.



Booth : #28171

CONTACT

PHONE :

(+54 11) 4489-8300

Address :

Gral. Juan Gregorio Lemos 2809 -

B1613AUE

Los Polvorines, Buenos Aires, Argentina.

WEBSITE : <http://elea-en.com.vnct3013.avnam.net/en/>

No. of Employees : 159

Revenue : \$32.8 M

■ About LABORATORIO ELEA PHOENIX S.A.

Elea has been developing products, medications and treatments for every medical specialty for over 80 years. Our mission is to boost constant innovation in the development of cutting-edge medicine and treatments that enhance people's life quality. From Argentina, to the world.

■ Therapeutic lines as of April 2023

Therapeutic Lines

[Anti-infectives >](#)

[Cosmetics >](#)

[Endocrinology >](#)

[HIV - Antivirals >](#)

[Neurosciences >](#)

[Onco-hematology >](#)

[Osteoarticular >](#)

[Pediatrics >](#)

[Rheumatology >](#)

[Women Health >](#)

[Antiparasitic >](#)

[Dermatology >](#)

[Flu antivirals >](#)

[Hematology >](#)

[OTC >](#)

[Oncology >](#)

[Otorhinolaryngology >](#)

[Pulmonary hypertension >](#)

[Urology >](#)

[Cardiometabolism >](#)

[Diabetes >](#)

[Gastroenterology >](#)

[Medical Clinic >](#)

[Odontology >](#)

[Ophthalmology >](#)

[Pain >](#)

[Respiratory >](#)

[Vaccines >](#)

Find out more about pipelines at <http://elea-en.com.vnct3013.avnam.net/en/>

Global offices

Buenos Aires, Argentina

Office in South Korea

N/A

Pharmaceutical Company

Laboratorio Varifarma & Blanver



Booth : # 6149

CONTACT

Email : info@varifarma.com.ar

Tel : (+54 11) 4723 2830

Address : Beccar, Buenos Aires Argentina

WEBSITE :

<https://www.varifarma.com/en/home-en/>

No. of Employees : 139 employees

Revenue : \$26M

About Laboratorio Varifarma & Blanver

Varifarma and Blanver have joined their efforts and portfolio of essential medicines for the treatment of diverse pathologies in order to improve the latinamerican patients' quality of life and well being. We are renowned for our products' high quality and our sustained commitment with the medical and scientific community in the areas of oncology, hematology, rare diseases and more. Together, Blanver & Varifarma support companies to succeed in Latin America market with innovator products.

Oncology Pipeline

ONCOLOGY

FEATURED

SUPROL ®

LENAVATIB®

RELOTIB®

CABAZIL ®

GEFIT ®

ACTIVE PRINCIPLE

Trifluridine and Tipiracil

Lenvatinib

Erlotinib

Cabazitaxel

Gefitinib

PRODUCT NAME

ANASTROZOL VARIFARMA ®

CABAZIL ®

CAPECITABINA VARIFARMA ®

CIPROFARMA ®

ACTIVE PRINCIPLE

Anastrozole

Cabazitaxel

Capecitabine

Cyproterone Acetate

Find out more about pipelines at

<https://www.varifarma.com/en/therapeutic-areas/oncology/>

Global Offices

Argentina (HQ), Chile, Peru,
Ecuador

Office in Korea

N/A

Pharmaceutical Company

Legend Biotech USA



Booth : # 27107

CONTACT

Tel : +1 (732) 317-5050

Address : Somerset, NJ

WEBSITE : <https://legendbiotech.com/>

No. of Employees : 831

Revenue : \$57 M

About Legend Biotech USA

Legend Biotech is a global biotechnology company dedicated to treating life-threatening diseases.

Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell (CAR-T) and natural killer (NK) cell-based immunotherapy.

Pipeline as of April 2023

					Global	US	China
Preclinical	Phase 1		Phase 2	Phase 3			
GASTRIC, ESOPHAGEAL & PANCREATIC [†] (CLAUDIN 18.2) Autologous	GASTRIC, ESOPHAGEAL & PANCREATIC [†] (CLAUDIN 18.2) Autologous NCT04467853	RRMM (BCMA) LEGEND-2 [†] Autologous NCT03090659	RRMM (BCMA)* CARTIFAN-1 Autologous NCT03758417	RRMM (BCMA)* 1-3 Prior Lines CARTITUDE-4 Autologous NCT04181827			
SCLC [†] (DLL3) Autologous	MM [†] (BCMA) Allogeneic – CAR-NK NCT05498545	NHL [†] /ALL [†] (CD19 X CD20 X CD22) [†] Autologous NCT05318963 NCT05292898	RRMM (BCMA)* CARTITUDE-1 Autologous NCT03548207	NDMM (BCMA)* Transplant Not Intended CARTITUDE-5 Autologous NCT04923893			
NSCLC (GPC3) Autologous	MM [†] (BCMA) Allogeneic – CAR-γδ T NCT05376345	HCC [†] (GPC3) Autologous NCT05352542	MM (BCMA)* CARTITUDE-2 Autologous NCT04133636	NDMM (BCMA)* Transplant Eligible CARTITUDE-6 Autologous NCT05257083			
COLORECTAL (GCC) Autologous							
AML (CLL1/CD33) Allogeneic							

Find out more about pipelines at <https://legendbiotech.com/research-development/pipeline/>

Global Offices	Office in Korea
China, Piscataway, Ireland, Belgium	N/A

Pharmaceutical Company

Melinta Therapeutics



Booth : # 11084

CONTACT

Tel : +1 908-617-1300

Address :

Parsippany, New Jersey 07054, US

Email:

medinfo@melinta.com

WEBSITE : <https://melinta.com/>

No. of Employees : 291

Revenue : \$96.4 M

■ About Melinta Therapeutics

Melinta Therapeutics provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes five commercial-stage antibiotics. With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that's how we make the most meaningful impact. We're visionaries dedicated to innovation while staying grounded in what matters most: patients.

- **Approved Products:** REZZAYO (rezafungin), Kimyrsa (oritavancin), VABOMERE (meropenem and vaborbactam), Orbactiv (oritavancin), Minocin (minocycline), Baxdela (delafloxacin),

■ Resources

Kimyrsa® (oritavancin) Patient assistance program

Kimyrsa® (oritavancin) Copay Savings Program

Orbactiv® (oritavancin) Patient assistance program

Orbactiv® (oritavancin) Copay savings program

Kimyrsa® (oritavancin) Colorado Prescriber Information

Vabomere® (meropenem and vaborbactam) Colorado Prescriber Information

Orbactiv® (oritavancin) Colorado Prescriber Information

Minocin® (minocycline) Colorado Prescriber Information

Baxdela® (delafloxacin) Colorado Prescriber Information

Baxdela® (delafloxacin) Vermont Long Form-Information for Vermont Prescribers of Prescription Drugs

Global Offices

Lincolnshire, Illinois 60069, US

Office in Korea

Pharmaceutical Company

Merck & Co., Inc.



Booth : # 6063

CONTACT

Tel : 1-908-740-4000

Address :

Rahway, NJ 07065 USA

WEBSITE : <https://www.merck.com>

No. of Employees : 69,000 employees

Revenue : \$59.3 B (2022)

■ About Merck & Co., Inc.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

■ Areas of focus

- Oncology, Vaccines, Infectious diseases, Cardio-metabolic disorders

■ Pipeline as of April 2023

Molecule Name	Therapeutic Area	Potential Indications	Status (i.e., Phase 2, 3, Under Review)	Modality
boremeststat (MK-3543)	Oncology	Myeloproliferative disorders		Small molecule
bosertolimab (MK-5890)	Oncology	Non-small cell lung cancer Small cell lung cancer		Monoclonal antibody
clesrovimab (MK-1654)	Respiratory	Respiratory syncytial virus		Monoclonal antibody
efinopegdutide (MK-6024)	Endocrinology	Nonalcoholic Steatohepatitis		Peptide
favezelimab (MK-4280)	Oncology	Non-small cell lung cancer		Monoclonal antibody
favezelimab + pembrolizumab (MK-4280A)	Oncology	Colorectal cancer Hematological malignancies Esophageal cancer Melanoma Renal cell carcinoma Small cell lung cancer		Monoclonal antibody fixed-dose combination

Find out more about pipelines at <https://www.merck.com/research/product-pipeline/>

Global Offices

247 office locations across 75 countries

Office in Korea

508 Teheran-ro, Daechi-dong, Gangnam-gu, Seoul

Pharmaceutical Company

Merus N.V.

Merus *closing in on cancer*

Booth : # 25163

CONTACT

Tel : +31 85 016 2500

Address :

3584 CT Utrecht, The Netherlands

WEBSITE : <https://merus.nl/>

No. of Employees : 132

Revenue : \$42 M (2022)

■ About Merus N.V.

At Merus, we are clinically advancing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer. Utilizing our proprietary technology platforms, we are developing innovative multispecific antibody therapeutics, referred to as Multiclonics®.

■ Pipeline as of April 2023

PROGRAM / TARGET / INDICATION	PRECLINICAL	PHASE 1	PHASE 1/2
Zenocutuzumab (Zeno, MCLA-128) BISPECIFIC TARGET: HER2 X HER3			
NRG1+ cancer			
NRG1+ NSCLC with afatinib			
Castration-resistant prostate cancer with androgen deprivation therapy			
Other non-NRG1+ cancer			
Petosemtamab (MCLA-158) BISPECIFIC TARGET: EGFR X LGR5			
2L+ Head and neck squamous cell carcinoma (HNSCC)			
1L HNSCC with a PD1 inhibitor			
MCLA-129 BISPECIFIC TARGET: EGFR X c-MET			
Solid tumors			
NSCLC third generation TKI			
MCLA-145 BISPECIFIC TARGET: CD137 X PD-L1			
Solid tumors			
Solid tumors with a PD1 inhibitor			

Find out more about pipelines at <https://merus.nl/pipeline/>

Global Offices	Office in Korea
Merus US Inc.	N/A
139 Main Street – Suite 302	
Cambridge, MA 02142	
USA	

Pharmaceutical Company

Mirati Therapeutics



Booth : # 21151

CONTACT

Tel : 1-844-647-2841

Address :

3545 Cray Court

San Diego, CA 92121

USA

WEBSITE : <https://www.mirati.com/>

No. of Employees : 132

Revenue : \$42 M (2022)

■ About Mirati Therapeutics

Mirati Therapeutics, Inc is a biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

■ Pipeline as of April 2023

Adagrasib (MRTX849)

KRAS^{G12C} Inhibitor

Adagrasib (MRTX849) is an investigational, highly selective and potent oral small molecule inhibitor of KRAS^{G12C} that is optimized to sustain target inhibition. This attribute could be important to treat KRAS^{G12C} mutated cancers, as the KRAS^{G12C} protein regenerates every 24 to 48 hours.

Development Approach	Lead Optimization	IND-Enabling	Phase 1/1b	Phase 2	Phase 3
Monotherapy	KRYSTAL-12: 2L NSCLC (Randomized to Docetaxel)				
	KRYSTAL-7: 1L NSCLC TPS <1%				
	KRYSTAL-1: Pancreatic and Other Tumors				
Combination with Cetuximab (EGFR)	Approved for 2L+ NSCLC as of Dec. 12, 2022				
	KRYSTAL-10: 2L CRC (Randomized to FOLFIRI or FOLFOX)				
Combination with Pembrolizumab (PD-1)	KRYSTAL-1: CRC				
	KRYSTAL-7: 1L NSCLC (2 Combination Arms <1% TPS and ≥1% TPS)				
POC Combinations: SOS1, RAF/MEK, mTOR, PD-1	2L+ NSCLC and CRC (Multiple Proof of Concept Combination Trials)				

Find out more about pipelines at <https://www.mirati.com/science/pipeline/>

Global Offices	Office in Korea
Switzerland: Mirati Therapeutics (Suisse) GmbH, Dammstrasse 19 6300 Zug	N/A

Pharmaceutical Company

Moderna



Booth : #22145

CONTACT

Email: APACmedinfo@modernatx.com

PHONE : +1-866-663-3762

Address :
200 Technology Square, Cambridge,
Massachusetts 02139, USA

WEBSITE : <https://www.modernatx.com/>


No. of Employees : 3,900 (2022)

Revenue : US\$19.26 billion (2022)

■ About Moderna

Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. In more than 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of mRNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.

■ Pipeline



Find out more about pipelines at <https://www.modernatx.com/research/product-pipeline>

Global offices

Other Locations & Subsidiaries:
United Kingdom, Italy, Austria,
France, Poland, Sweden and Japan

Moderna Office in South Korea

Address :
76, Saemun-ro, Jongno-gu,
Seoul, Republic of Korea
Phone : +82-80-001-4589
Fax : N/A

Pharmaceutical Company

MorphoSys AG



BOOTH : # 26117

CONTACT

Email : info@morphosys.com

PHONE : +49 (0)89 / 899 27-0

Address :
MorphoSys AG,
Simmelweisstr. 7
82152 Planegg, Germany

WEBSITE : <https://www.morphosys.com>

No. of Employees : 615 (2020)

Revenue : €327.7 million (2020)

■ About MorphoSys AG

MorphoSys is a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer. With the acquisition of Constellation Pharmaceuticals in July 2021, MorphoSys is building a significant presence in hematology-oncology. Being able to help patients and aiming to provide them with the best treatment available is the strongest motivation driving our more than 750 employees across Germany and the United States.

■ Approved Medicines

- Monjuvi (tafasitamab-cxix)

■ Pipeline

Compound / Brand name	Indication	NCT	Phase 1	Phase 2	Phase 3	Market	Alle
Tafasitamab Target CD19	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only - accelerated approval)	02399085					
	Diffuse large B-cell lymphoma (DLBCL) (frontMIND)	04824092					
	Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)	04680052					
	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (B-MIND)	02763319					

Find out more about pipelines at <https://www.morphosys.com/en/our-pipeline>

Global Offices	Office in Korea
USA MorphoSys US Inc. Address: 470 Atlantic Avenue, Suite 1401 Boston, MA 02210 Tel : (844) 667-1992 Email : info.us@morphosys.com	N/A

Pharmaceutical Company

Northwest Biotherapeutics, Inc.



BOOTH : # 12153

CONTACT

Email : media@nwbio.com

PHONE : 240-497-9024

Address :
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814

WEBSITE : <http://www.nwbio.com>

No. of Employees : 33 (2022)

Revenue : \$1.7 M (2022)

About Northwest Biotherapeutics, Inc.


Northwest Biotherapeutics is developing DCVax® personalized dendritic cell-based therapeutic vaccines for solid tumors. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for Glioblastoma, the most aggressive and lethal form of brain cancer. This Phase III trial is completed and the trial data are being analyzed. The Company has also treated a variety of other solid tumors, with encouraging results, in compassionate use cases and other clinical trials.

Product

- DCVax –L
- DCVax – Direct
- DCVax – Prostate

Pipeline

Robust Pipeline of Clinical Trials



Find out more about pipelines at <https://nwbio.com/clinical-trials/pipeline/>

Global Offices

Other Locations & Subsidiaries:

- NW Biotherapeutics GmbH
- > Germany
- Aracaris Capital Ltd
- > United Kingdom
- Aracaris Ltd
- > United Kingdom
- Flaskworks LLC
- > United States of America

Office in Korea

N/A

Pharmaceutical Company

Notable Labs



Booth : #23140

CONTACT

Email: info@notablelabs.com

PHONE : +1- (415) 851-2410

Address :

320 Hatch Drive,
Foster City, CA 94404, USA

WEBSITE : <https://notablelabs.com/>




No. of Employees : 25

Revenue : <\$5M

■ About Notable Labs

Notable Labs ("Notable") is a technology enabled biotechnology company developing a portfolio of precision medicines supported by machine learning analytics and cellular intelligence technologies to improve trial success, accelerate development, and improve cost efficiencies. Notable's predictive platform is clinical validated through 4 studies and has demonstrated ability to identify responders before treatment with precision and accuracy. Notable predictive platform is currently being used to advance clinical stage assets through FDA trials with improved likelihood of success.

■ Pipeline

Molecule	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Development Rights
NBL-001 (Volasertib)	Acute Myeloid Leukemia (AML)					 Notable
	Pediatric Leukemia					
	Solid Tumors					
Fosciclipirox	AML					 Notable  CicloMed

Notable is actively seeking assets to in-license that would benefit from our platform.

Find out more about pipelines at <https://notablelabs.com/therapeutic-pipeline/>

Global offices

N/A

Moderna Office in South Korea

N/A

Pharmaceutical Company

NOVARTIS Pharmaceuticals Corporation



BOOTH : # 5083

CONTACT

Address : 18 Fabrikstrasse, Basel, Basel-City, 4056, Switzerland

PHONE: +41 613241111

WEBSITE : <https://www.novartis.com/>


No. of Employees : 101,703

Revenue : US\$50.545 billion (2022)

■ About NOVARTIS Pharmaceuticals Corporation

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.

■ Pipeline



Find out more about pipelines at <https://www.hcp.novartis.com/medical/pipeline-navigator/>

Global Offices

+1 862 778 21 00

Office in Korea

49th Floor, Three IFC, 10.
Gukjegeumyung-ro.
Yeongdeungpo-gu. Seoul.

+82-2-768-9000

Pharmaceutical Company

Novocure Inc.

novocure®

BOOTH : # 4096

CONTACT

PHONE : +34 629238543

Address : The Forum second floor
Grenville St No 4, Saint Helier, JE2 4UF,
Jersey

WEBSITE :

<https://virtualcongress.novocure.com/>

No. of Employees : 1,320

Revenue : \$537.8M

■ About Novocure Inc.

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields (TTFields). Novocure's commercialized products are approved in the United States for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma.

■ Pipeline



Find out more about pipelines at <https://www.novocure.com/our-pipeline/>

Global Offices	Office in Korea
US, Europe, Japan and Israel	N/A

Pharmaceutical Company

ONO Pharma



BOOTH : # 4147

CONTACT

Email :
public_relations@ono-pharma.com

PHONE : +81-6-6263-5670

Address : 8-2, Kyutaromachi 1-chome,
Chuo-ku, Osaka 541-8564, Japan

WEBSITE : <https://www.ono-pharma.com>

No. of Employees : 3,576 (2018)

Revenue : JPY 261.8 billion (FY 2017)
(US\$ 2.4 billion) (FY 2017)

About ONO Pharma

ONO PHARMA USA is pursuing the clinical development of new drug candidates in oncology, immunology, neurology, and specialty research that it aims to commercialize in the U.S. ONO PHARMA USA was established as a subsidiary of ONO Pharmaceutical Co., Ltd., in 1998. ONO was founded in Osaka, Japan, in 1717, and is now a global R&D-oriented pharmaceutical company committed to discovering and developing “first-in-class” medicines, such as nivolumab, an anti-PD-1 antibody.

Pipeline

Oncology

As of Jan 23, 2023

Product Name	Mechanism	Target Disease	Development Stage					Country / Region	Licensor
			1	2	3	Filing	Approval		
ONO-4059	BTK inhibitor	Primary central nervous system lymphoma						JP · KR · TW	In-house
								US	
		Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma						JP	
ONO-7475	Axl/Mer inhibitor	Solid tumor ★						JP	In-house
		EGFR mutation-positive non-small cell lung cancer						JP	
ONO-4685	PD-1 x CD3 bispecific antibody	T-cell lymphoma						US	In-house
ONO-4578	PG receptor (EP4) antagonist	Solid tumor · Gastric cancer ★						JP	In-house
		Colorectal cancer ★						JP	
		Pancreatic cancer ★						JP	
		Non-small cell lung cancer ★						JP	
		Hormone receptor-positive, HER2-negative breast cancer						JP	

Find out more about pipeline at <https://us.ono-pharma.com/science/pipeline>

Global Offices

Overseas Subsidiaries :
United Kingdom, USA and Taiwan

Office in Korea

ONO PHARMA KOREA CO., LTD,
Seoul (South Korea)

19F, POSCO TOWER YEOKSAM,
134, Teheran-ro, Gangnam-gu,
Seoul, 06235, South Korea

TEL : +82-2-928-8423

Pharmaceutical Company

Pfizer Oncology



Booth : # 6043

CONTACT

Email: PfizerMediaRelations@pfizer.com

PHONE : +1-800-879-3477

Address : Pfizer Inc.

235 East 42nd Street

New York NY 10017 USA

WEBSITE : <http://www.pfizer.com>

No. of Employees : 83,000 (2022)

Revenue : US\$100.3 billion (2022)

■ About Pfizer Oncology

At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine

■ Pipeline

PF-06835375

Phase 1 Inflammation & Immunology New Molecular Entity Biologic Current

Lupus (Biologic)

anti-CXCR5

PF-07054894

Phase 1 Inflammation & Immunology New Molecular Entity Small Molecule Current

Inflammatory Bowel Disease

CCR6 Antagonist

PF-07242813

Phase 1 Inflammation & Immunology New Molecular Entity Biologic Current

Atopic Dermatitis (Biologic)

CD1a inhibitor

PF-07295324

Phase 1 Inflammation & Immunology New Molecular Entity Small Molecule Current

Atopic Dermatitis

Topical Soft JAK Inhibitor

Find out more about pipeline at <https://www.pfizer.com/science/drug-product-pipeline>

Global Offices

39 manufacturing sites and 11
distribution/logistics centers

Office in Korea

100, Toegye-ro, Jung-gu, Seoul,
Republic of Korea 04631,
Phone: +82-2-317-2114

Pharmaceutical Company

Pharmacosmos Therapeutics Inc.

PHARMACOSMOS
T H E R A P E U T I C S

Booth : # 21101

CONTACT

Email : info@pharmacosmos.com.

PHONE : (973) 267-2205

Address : 30 Roervangsvej, Holbaek,
Central Jutland, DK-4300, Denmark

WEBSITE :

<https://www.pharmacosmos.com/>

No. of Employees : 450

Revenue : \$120M

■ About Pharmacosmos Therapeutics Inc.

Pharmacosmos Therapeutics Inc. is a U.S. specialty pharmaceutical company dedicated to providing patient care through the commercialization of Monofer[®] (ferric derisomaltose) injection and through exceptional resources to support this treatment. They are the U.S. affiliate of the Denmark-based Pharmacosmos Group.

■ Products

HUMAN IRON

- Monofer[®] - ferric derisomaltose
- Diafer[®] - 5% ferric derisomaltose
- Cosmofer[®] - Low Mw Iron Dextran

VETERINARY IRON

- Uniferon[®] - Iron(III) Dextran

Find out more about products at

<https://www.pharmacosmos.com/pharmacosmos/products>

Global Offices	Office in Korea
US, China, UK, Ireland, Germany, Sweden and Norway	N/A

Pharmaceutical Company

Pharmacyclics LLC, an AbbVie Company



Booth : # 18161

CONTACT

PHONE : (408) 215-3000

Address : 995 E Arques Ave, Sunnyvale,
California, 94085, United States

WEBSITE :

<https://www.pharmacyclics.com/>

No. of Employees : 607

Revenue : \$235.0M (2022)

■ About Pharmacyclics LLC, an AbbVie Company

Pharmacyclics is an AbbVie Company in South San Francisco, California, developing and commercializing small-molecule medicines for which there is great unmet medical need.

■ Area of Study

Ibrutinib: Bruton's tyrosine kinase (BTK) inhibitor

Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)	Completed
All Lines of Treatment	✓ Ibrutinib
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)	Completed
Previously Treated Patients	✓ Ibrutinib vs. Ofatumumab
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)	Completed
First Line Treatment Elderly and/or Unfit Patients	✓ Ibrutinib vs. Chlorambucil
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)	Completed
Previously Treated Patients	✓ Ibrutinib w/ BR vs. BR

Find out more informations at <https://www.pharmacyclics.com/home/areas-of-study.html>

Global Offices

N/A

Office in Korea

N/A

Pharmaceutical Company

PharmaEssentia USA Corporation



Booth : # 21168

CONTACT

PHONE : (617) 245-2200

Address : 2f-5 No. 3 Park St, Nangang District, Taipei, 115, Taiwan

WEBSITE :

<https://us.pharmaessentia.com/>

No. of Employees : 131

Revenue : \$22.1M

About PharmaEssentia USA Corporation

The PharmaEssentia Medical Affairs team are strategic thought partners dedicated to providing comprehensive educational, clinical, and scientific information about PharmaEssentia therapies and areas of interest, and engaging in meaningful discussions with healthcare professionals and key stakeholders about our pipeline and the unmet medical needs in myeloproliferative neoplasms. The transformative and actionable insights gained through scientific exchange lead to the development of innovative evidence generation strategies and educational opportunities.

Pipeline



Find out more about pipeline at <https://us.pharmaessentia.com/focus-mpn/pipeline/>

Global Offices

Subsidiaries :

- PharmaEssentia USA Corp.
- PharmaEssentia Japan KK
- PharmaEssentia Asia (Hong Kong) Limited
- PharmaEssentia Biotechnology (Beijing) Ltd.
- PharmaEssentia Singapore Pte. Ltd.

Office in Korea

PharmaEssentia Korea Corp.

Unit 2022, 20F Gwanghwamun Building, 149 Sejong-daero, Jongno-gu, Seoul

+82-2-2109 4928

Pharmaceutical Company

PharmaMar



Booth : # 26135

CONTACT

Email : pharmamar@pharmamar.com

PHONE : +34 91 846 6000

Address : Avda. De los Reyes, 1
28770 - Colmenar Viejo, Madrid, Spain

WEBSITE :

<https://www.pharmamar.com/>


No. of Employees :

Revenue : €162.6 million (2018)

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare of patients with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients. It is the world leader in marine medicinal discovery and development. PharmaMar commercializes Yondelis in Europe and Zepzelca in Switzerland by itself, as well as outside Europe with different partners for Yondelis, Zepzelca and Aplidin. In addition, it has a pipeline of drug candidates and a robust R&D oncology program.

Pipeline



Find out more about pipeline at <https://pharmamar.com/en/investors/pipeline/>

Global Offices

Other Locations & Subsidiaries:

- Promaxsa Proteccion de Maderas, S.L, Sylentis SAU and Noscira S.A.

> Spain

Genomica (Wuhan) Trading Co.Ltd.

China

- PharmaMar AG

> Switzerland

- PharmaMar SARL

> France

- PharmaMar USA Inc

> USA

Office in Korea

N/A

Pharmaceutical Company

Prothena



Booth : # 8037

CONTACT

Email : info@prothena.com

PHONE : +353 1 236 2500

Address : Prothena Corporation plc
77 Sir John Rogerson's Quay, Block C
Grand Canal Docklands, Dublin 2, D02
VK60, Ireland

WEBSITE : <https://www.prothena.com/>

No. of Employees : 127 (2022)

Revenue : \$53.9 M (2022)

■ About Prothena

Prothena® Corporation PLC is a late-stage clinical biotechnology company with expertise in protein dysregulation. Fueled by a deep scientific expertise built over decades of research, Prothena combines its expertise in protein dysregulation and rigorous scientific approach to develop therapeutic candidates with best-in-class potential. The pipeline of investigational therapeutics at Prothena has the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases, diseases which affect millions of people and their families worldwide.

■ Pipeline

TARGET & PRODUCT	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
✓ Birtamimab Kappa & Lambda Light Chain	AL Amyloidosis					
✓ Prasinezumab α-Synuclein (C-terminus)	Parkinson's Disease					
✓ NNC6019/PRX004 Transthyretin (misTTR)	ATTR Amyloidosis					
✓ PRX005 Tau (MTBR)	Alzheimer's Disease					
✓ PRX012 Aβ (N-terminus)	Alzheimer's Disease					
✓ PRX123 Aβ + Tau	Alzheimer's Disease					
✓ PRX019	Neuro-degeneration					
✓ TDP-43	ALS					
✓ Undisclosed	AD in Down Syndrome					

Find out more about pipeline at <https://www.prothena.com/pipeline/>

Global Offices

Prothena Biosciences Inc
331 Oyster Point Boulevard
South San Francisco, CA 94080,
U.S.A.
TEL +1 650 837 8550
FAX +1 650 837 8560

Office in Korea

N/A

Pharmaceutical Company

Rain Oncology Inc.



Booth : # 17171

CONTACT

Email : info@rainoncology.com

PHONE : 510-953-5559

Address : 8000 Jarvis Ave Suite 204
Newark, CA 94560 USA

WEBSITE :

<https://www.rainoncology.com/>


No. of Employees : > 60

Revenue : \$14.9M

■ About Rain Oncology Inc.

Rain Oncology is a clinical-stage precision oncology company. Our uncompromised dream is to develop and implement the best precision oncology therapies for patients suffering from cancer. We are rooted in this purpose — extending the quality and length of life for cancer patients where we may be their best hope.

■ Pipeline



Find out more about pipeline at <https://www.rainoncology.com/pipeline>

Global Offices	Office in Korea
N/A	N/A

Pharmaceutical Company

RayzeBio



Booth : # 18129

CONTACT

Email : info@rayzebio.com

PHONE : +1 (858) 257-3449

Address : RayzeBio, Inc.
5505 Morehouse Drive, Suite 300
San Diego, CA 92121, USA

WEBSITE : <https://rayzebio.com/>

No. of Employees : 53

Revenue : <\$5M

■ About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. Established in 2020, RayzeBio is backed by a syndicate of sophisticated healthcare investors.

■ Pipeline



Find out more about pipeline at <https://rayzebio.com/pipeline/pipeline-overview/>

Global Offices

N/A

Office in Korea

N/A

Pharmaceutical Company

Regeneron Pharmaceuticals

REGENERON®

Booth : # 19005

CONTACT

PHONE : +1 914-847-7000

Address : 777 Old Saw Mill River Road
Tarrytown, NY 10591, USA

WEBSITE : <https://www.regeneron.com/>

No. of Employees : 11,851

Revenue : \$3.414B (2022)

About Regeneron Pharmaceuticals

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development.

Pipeline

Phase 1	Phase 2	Phase 3
<p>ALN-APP¹ RNAi therapeutic targeting APP Early-onset Alzheimer's disease Neurology General Medicine</p> <p>ALN-HSD RNAi therapeutic targeting HSD17B13 Nonalcoholic steatohepatitis ("NASH") Immunology & Inflammation General Medicine</p> <p>ALN-PNP¹ RNAi therapeutic targeting PNPLA3 NASH General Medicine</p> <p>FIANLIMAB Antibody to LAG-3 Solid tumors and advanced hematologic malignancies Oncology Hematology</p> <p>LINVOSELTAMAB Bispecific antibody targeting BCMA and CD3 Multiple myeloma Hematology</p> <p>"NEXT GENERATION" COVID ANTIBODIES Antibodies to SARS-CoV-2 Variants Healthy volunteers Infectious Diseases General Medicine</p>	<p>CEMPIIMAB Antibody to PD-1 Neoadjuvant CSCC; Second-line cervical cancer, ISA101b combination Oncology</p> <p>LINVOSELTAMAB Bispecific antibody targeting BCMA and CD3 Multiple myeloma (pivotal study) Oncology Hematology</p> <p>MIBAVADEMAB Agonist antibody to leptin receptor ("LEPR") Generalized lipodystrophy; Partial lipodystrophy Cardiovascular & Metabolic Diseases Rare Diseases General Medicine</p> <p>ODRONEXTAMAB⁵ Bispecific antibody targeting CD20 and CD3 B-cell non-Hodgkin lymphoma ("B-NHL") (pivotal study) Cardiovascular & Metabolic Diseases Oncology Hematology</p> <p>POZELIMAB Antibody to CS5; studied as monotherapy and in combination with cemdisiran CD55-deficient protein-losing enteropathy ("CHAPLE"), monotherapy (potentially pivotal study) Oncology</p>	<p>AFLIBERCEPT 8MG² VEGF-Trap Wet AMD, DME Ophthalmology</p> <p>AFLIBERCEPT² VEGF-Trap ROP Ophthalmology</p> <p>ALIROCUMAB Antibody to PCSK9 HeFH in pediatrics Cardiovascular & Metabolic Diseases General Medicine</p> <p>CEMPIIMAB Antibody to PD-1 Adjuvant CSCC Oncology</p> <p>DUPILUMAB⁵ Antibody to IL-4R alpha subunit EoE in pediatrics; chronic obstructive pulmonary disease ("COPD"); bullous pemphigoid (Phase 2/3); chronic spontaneous urticaria ("CSU"); chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyps; allergic fungal rhinosinusitis; chronic pruritis of unknown origin Immunology & Inflammation</p> <p>FIANLIMAB Antibody to LAG-3 First-line metastatic melanoma, First-line</p>

Find out more about pipeline at <https://www.regeneron.com/pipeline-medicines/investigational-pipeline>

Global Offices	Office in Korea
Netherlands, India, Ireland, United Kingdom and Germany	N/A

Pharmaceutical Company

Replimune



Booth : # 6161

CONTACT

Email : info@replimune.com

PHONE : (781) 222-9600

Address : Replimune Group Inc.
500 Unicorn Park Dr., 3rd Floor
Woburn MA 01801, USA

WEBSITE : <https://replimune.com/>

No. of Employees : 206

Revenue : \$69.5M

■ About Replimune

Replimune Group, Inc. is a clinical stage biotechnology company with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune's proprietary RPx drug discovery platform is based on a potent HSV-1 backbone with added transgene payloads designed to maximize direct selective viral killing of the tumor and alters the tumor microenvironment (TME), triggering the release of tumor derived antigens to ignite a strong and durable systemic immune response across different cancers.

■ Pipeline



Find out more about pipeline at <https://replimune.com/pipeline/>

Global Offices	Office in Korea
UK Replimune Ltd. 69 Innovation Drive, Milton Park Abingdon OX14 4RQ	N/A

Pharmaceutical Company

Rigel Pharmaceuticals



Booth : # 20134

CONTACT

Email : ir@rigel.com

PHONE : (650) 624-1100

Address : Rigel Pharmaceuticals, Inc.
611 Gateway Blvd
Suite 900
South San Francisco, CA 94080, USA

WEBSITE : <https://www.rigel.com/>

No. of Employees : 307

Revenue : \$51.3M

■ About Rigel Pharmaceuticals

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Rigel has 2 FDA approved products: 1. TAVALISSE (fostamatinib disodium hexahydrate) tablets was approved in 2018. Please visit www.TAVALISSEhcp.com to see the Full Prescribing Information to learn more. 2. REZLIDHIA (olutasidenib) capsules was approved in 2022.

■ Pipeline

Commercialized Products

TAVALISSE® (fostamatinib)¹
Adult Chronic Immune
Thrombocytopenia (ITP)
Target: Spleen tyrosine kinase (SYK)

PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED

REZLIDHIA™ (olutasidenib)²
R/R Acute Myeloid Leukemia
Target: Mutant isocitrate
dehydrogenase-1 (mIDH1)

PRE-CLINICAL PHASE 1 PHASE 2 NDA FILED APPROVED

Clinical Trials

Fostamatinib³
COVID-19
Target: Spleen tyrosine kinase (SYK)

PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED

Fostamatinib³ - ACTIV4 Host Tissue⁴
COVID-19
Target: Spleen tyrosine kinase (SYK)

PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED

R289⁵
LR-MDS & Immune Diseases
Target: Interleukin receptor-associated
kinases 1 and 4 (IRAK1/4)

PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED

Find out more about pipeline at <https://www.rigel.com/pipeline>

Global Offices

N/A

Office in Korea

N/A

Pharmaceutical Company

RS Oncology, LLC.



Booth : # 23144

CONTACT

Email : info@rsoncology.com

Address : RS Oncology, LLC
Cambridge Innovation Center
One Broadway
14th Floor
Cambridge MA 02142, USA

WEBSITE :
<https://www.rsoncology.com/>


No. of Employees : <25

Revenue : <\$5M

■ About RS Oncology, LLC.

RS Oncology is a private biotech company based in Cambridge, MA USA. As a team of seasoned executives, scientists, and drug developers, we are building global partnerships to innovate new therapies. Our mission is to improve the lives and outcomes of patients with debilitating diseases and unmet medical needs. RSO-021, our initial program, represents a novel class of oncology compounds that irreversibly bind and inhibit a key enzyme (PRX3) within the mitochondria of malignant cells. Currently in Phase 1/2 clinical development. ClinicalTrials.gov Identifier: NCT05278975.

■ Pipeline



Find out more about pipeline at <https://www.rsoncology.com/pipeline>

Global Offices	Office in Korea
N/A	N/A

Pharmaceutical Company

Sanofi



Booth : # 10097

CONTACT

PHONE : +33 1 53 77 40 00

Address : the 17th arrondissement of Paris, at 46-48 Avenue de la Grande Armée

WEBSITE :

<https://www.sanofioncology.com/>

No. of Employees : 91,573 (2022)

Revenue : €42.99 billion (2022)

About Sanofi

Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to help improve people's lives. We are working to advance potentially transformative therapies to help people with cancer. Our current work and research focuses on lung, prostate, multiple myeloma and other blood cancers. We take bold steps every day to advance our pipeline and seek solutions that help address critical gaps in care across a variety of difficult-to-treat cancers.

Pipeline

Therapeutic Area	Phase	Name	Description	Indication
Immunology & Inflammation	1 2 3 R	SAR441566	1 Oral TNF inhibitor	Inflammatory indication
Immunology & Inflammation	1 2 3 R	SAR442970	1 Anti-TNFα/OX40L NANOBODY® VHH	Inflammatory indication
Immunology & Inflammation	1 2 3 R	SAR443765	1 Anti-IL-13/TSLP NANOBODY® VHH	Inflammatory indication
Immunology & Inflammation	1 2 3 R	SAR444336	1 Non-beta IL-2 SYNTHORIN™	Inflammatory indication
Immunology & Inflammation	1 2 3 R	SAR444656	1 IRAK4 degrader	Atopic dermatitis
Immunology & Inflammation	1 2 3 R	SAR444419	1 Anti-TNFα/IL6 NANOBODY® VHH	Inflammatory indication New
Immunology & Inflammation	1 2 3 R	SAR444559	1 Anti-CD38 mAb Next Generation	Inflammatory indication New

Find out more about pipeline at <https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline>

Global Offices

Sanofi US Headquarters
55 Corporate Drive
Bridgewater, NJ 08807
Phone: 800-981-2491

Office in Korea

235, Banpo-daero, Seocho-gu,
Seoul, Republic of Korea
(02)2136-9000

Pharmaceutical Company

Seagen



Booth : # 18025, #CF8

CONTACT

Email : contact@seagen.com

PHONE : +1-425-527-4000

Address : 21717 30th Drive S.E., Building
3 Bothell, WA 98021, USA

WEBSITE : <https://www.seagen.com/>


No. of Employees : 3,256 (2022)

Revenue : \$1.96 B (2022)

■ About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary antibody-drug conjugates and immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors.

■ Pipeline



Find out more about pipeline at <https://www.seagen.com/science/pipeline>

Global Offices

Switzerland, Denmark, France,
Germany, Italy, Netherlands,
Spain and United Kingdom

Office in Korea

N/A

Pharmaceutical Company

Servier Pharmaceuticals LLC



Booth : # 18005

CONTACT

PHONE : +33 155726000

Address : 50 Rue Carnot, Suresnes,
Wallis and Futuna, 92284, France

WEBSITE : <https://servier.com/>

No. of Employees : 21,400

Revenue : €4.2 billion (FY 2018)

■ About Servier Pharmaceuticals LLC

Servier Pharmaceuticals is a commercial-stage pharmaceuticals company with a passion for innovation and improving the lives of patients, their families and caregivers. In the United States, Servier Pharmaceuticals is committed to building a robust portfolio, starting with oncology, with future growth driven by innovation in other areas of unmet medical need, leveraging Servier's global portfolio and seeking acquisitions, licensing deals and partnerships.

■ Pipeline

Oncology

SOLID TUMOURS

Compound / MA	Project	Therapeutic area	Phase
FTD/TPI + bevacizumab	S95005	Solid tumours (new indication)	CRP 1 2 3
Futuximab / modotuximab + FTD/TPI	S95026	Solid tumours (new indication)	CRP 1 2 3
Vorasidenib	S95032	Low-grade glioma with IDH1/2 mutation	CRP 1 2 3
Ivosidenib	S95031	Solid tumours (new indication)	CRP 1 2 3
Anti-MET	S95027	Non-small cell lung cancer	CRP 1 2 3
Vorasidenib + pembrolizumab	S95032	Grade 2/3 glioma with IDH1/2 mutation	CRP 1 2 3
Ivosidenib in combination	S95031	Solid tumours (new indication)	CRP 1 2 3
Anti-TIM3 in combination	S95018	Solid tumours	CRP 1 2 3

Find out more about pipeline at <https://servier.com/expertises/pipeline-developpement/>

Global Offices

- 16 production sites,
- 6 research centers
- 3 hubs
(North and South America,
Europe, Asia-Pacific) with 15
International Centers for
Therapeutics Research

Office in Korea

23F, 24, Yeoui-daero,
Yeongdeungpo-gu, Seoul,
Republic of Korea (07320)
Tel. +82-2-3415-8500,
FAX. +82-2-3415-8502~3

Pharmaceutical Company

Simcere



Booth : # 26155

CONTACT

PHONE : +86 025 85566666

Address : 699-18 Xuanwu Avenue
Nanjing China (210042)

WEBSITE : <http://simcere.com/>


No. of Employees : > 6,500

Revenue : RMB 5,000 million
or USD 788.3 million (2021)

About Simcere

Simcere is an innovation and R&D-driven pharmaceutical company with a focus on three therapeutic areas, oncology, central nervous system and autoimmune diseases aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D and commercial stage collaborations have made it a strategic alliance partner with world-leading innovative companies and research institutes.

Pipeline



Find out more about pipeline at <https://en.simcere.com/kxcx/yfgx.aspx>

Global Offices

Simcere Boston Innovation
Center (Boston R&D Center)
Address : 20 Acorn Park Dr,
Cambridge, MA 02140 USA

Office in Korea

N/A

Pharmaceutical Company

Spectrum Pharmaceuticals, Inc.



Booth : # 4125

CONTACT

PHONE : (617) 586-3900

Address : Pilot House - Lewis Wharf
2 Atlantic Avenue, 6th Floor
Boston, MA 02110, USA

WEBSITE : <https://www.sppirx.com/>


No. of Employees : 164 (2021)

Revenue : \$55.4M

■ About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace.

■ Pipeline



Find out more about pipeline at <https://www.sppirx.com/300-spectrum-products-portfolio.html>

Global Offices

- Spectrum and Cayman LP
- > United Kingdom
- Spectrum Pharma Canada Inc
- > Canada
- Spectrum Pharmaceuticals International Holdings LLC
- RIT Oncology, LLC
- Talon Therapeutics Inc
- > United States of America
- Spectrum Pharmaceuticals BV
- > Netherlands
- United States of America
- Spectrum Oncology Pvt Ltd
- > India

Office in Korea

N/A

Pharmaceutical Company

SpringWorks Therapeutics



Booth : # 16169

CONTACT

Email : info@springworkstx.com

PHONE : 203-883-9490

Address : Connecticut office
100 Washington Blvd
Stamford, CT 06902, USA

WEBSITE : <https://springworkstx.com/>


No. of Employees : 227

Revenue : \$48M

About SpringWorks Therapeutics

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers.

Pipeline



Find out more about pipeline at <https://springworkstx.com/pipeline/>

Global Offices	Office in Korea
Other Location & Subsidiaries : - SpringWorks Therapeutics, LLC - SpringWorks Subsidiary (1,2,3 and 4) Inc. - MapKure LLC - SpringWorks Therapeutics Operating Company, Inc. > United States of America	N/A

Pharmaceutical Company

Stemline Therapeutics, Inc.



A Menarini Group Company

Booth : # 2117

CONTACT

PHONE : 646-502-2310

Address : Stemline Therapeutics, Inc.
750 Lexington Avenue, 11th Floor
New York, NY 10022

WEBSITE : <https://stemline.com/>

No. of Employees : 100

Revenue : \$43.2M

■ About Stemline Therapeutics, Inc.

Menarini and Stemline are committed to make a difference in cancer patients' lives. We invest in the development of precision medicine through our pipeline of investigational drugs, which includes investigating both small molecules and biologics in hematologic and solid tumors. Partnering with cancer experts and research institutions around the world, we want to constantly improve our understanding of cancer to enable personalized care from early detection to precision medicine.

■ Pipeline

COMPOUND	MECHANISM OF ACTION	INDICATION	STAGE	ADDITIONAL DETAIL	EXTERNAL LINKS
TAGRAXOFUSP	Targeted Biologic (CD123)	BPDCN	Approved (US)	ELZONRIS was approved by the U.S. FDA in 2018 for the treatment of adult and pediatric patients, 2 years or older, with BPDCN.	Important Safety Information
		BPDCN	Approved (EU)	ELZONRIS was approved by the EMA in 2021 as monotherapy for the first-line treatment of adult patients with BPDCN.	Important Safety Information
		AML	Phase 2	TAGRAXOFUSP is being investigated for treatment of Acute Myeloid Leukemia (AML)	
		CMML	Phase 2	TAGRAXOFUSP is being investigated for treatment of chronic myelomonocytic leukemia (CMML)	
		MF	Phase 2	TAGRAXOFUSP is being investigated for treatment of Myelofibrosis (MF)	

Find out more about pipeline at <https://stemline.com/product-pipeline/>

Global Offices	Office in Korea
Stemline Therapeutics GmbH Address : Grafenastrasse 3, CH-6300 Zug, Switzerland	N/A

Pharmaceutical Company

Sumitomo Pharma Oncology



Booth : # 17109

CONTACT

PHONE : +81-6-6203-5321

Address : 6-8, Doshomachi 2-chome,
Chuo-ku, Osaka 541-0045, Japan

WEBSITE : <https://oncology.sumitomo-pharma.com/>

No. of Employees : 251-500

Revenue : \$26.7M

■ About Sumitomo Pharma Oncology

Sumitomo Pharma Oncology, Inc. is a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SMP Oncology is committed to the goal of advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. SMP Oncology's robust and diverse pipeline of preclinical and clinical-stage assets spans multiple areas, including oncogenic pathways, survival mechanisms and novel protein interactions, which aim to address unmet clinical needs in oncology.

■ Pipeline

Hematologic malignancies

TP-3654

PIM1 inhibitor
Myelofibrosis

Phase I / II

DSP-5336

Menin-MLL binding inhibitor
AML and ALL

Phase I / II

Solid tumors

TP-1287

CDK9 inhibitor
Advanced solid tumors

Phase I

DSP-0390

EBP inhibitor
Recurrent, high-grade glioma

Phase I

TP-1454

PKM2 inhibitor
Advanced solid tumors

Phase I

DSP-0509

TLR7 agonist
Advanced solid tumors

Phase I / II

Find out more about pipeline at <https://oncology.sumitomo-pharma.com/pipeline/>

Global Offices

Subsidiaries :
USA, China, Thailand, Taiwan,
Vietnam, Malaysia and Singapore

Office in Korea

N/A

Pharmaceutical Company

Sutro Biopharma



Booth : # 5149

CONTACT

Email : general@sutro.bio

PHONE : 650-881-6500

Address : 111 Oyster Point Blvd
South San Francisco, CA 94080, USA

WEBSITE : <https://www.sutro.bio/>

No. of Employees : 234

Revenue : \$53.1M

About Sutro Biopharma

Sutro Biopharma is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro's platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines directed at precedented targets in clinical indications where the current standard of care is suboptimal.

Pipeline



Find out more about pipeline at <https://www.sutro.bio/pipeline/>

Global Offices

N/A

Office in Korea

N/A

Pharmaceutical Company

SystImmune Inc.



Booth : # 20168

CONTACT

PHONE : (425) 453-6841

Address : 15318 NE 95th St, Redmond,
Washington, 98052, United States

WEBSITE :
<https://www.systimmune.com/>










No. of Employees : 32

Revenue : \$7.2M

■ About SystImmune Inc.

SystImmune is a biopharmaceutical company focused on the development of novel bi-specific and multi-specific antibodies, as well as antibody-drug conjugates (ADCs) for the treatment of cancer. Our goal is to create biologics that directly attack tumors, intervene in tumor microenvironments, and activate the immune system against tumors. We have eight in-house developed assets in clinical testing. SystImmune is committed to driving systematic intervention in oncology using clinical and preclinical sciences, to achieve therapeutic impact for patients and their families.

■ Pipeline

Molecule	Targets	Platform	Indication	Phase
 SI-B001	EGFR, HER3	SEBA	Solid tumor	2
 SI-B003	CTLA-4, PD-1	SEBA	Solid tumor	2
 GNC-038	CD3, 41BB, PD-L1, CD19	GNC	Lymphoma, leukemia	2
 GNC-035	CD3, 41BB, PD-L1, ROR1	GNC	Lymphoma, leukemia, solid tumor	1
 GNC-039	CD3, 41BB, PD-L1, EGFRvIII	GNC	Glioblastoma	1
 BL-B01D1	Bispecific	HIRE-ADC	Solid tumor	1
 BL-M02D1	Monospecific	HIRE-ADC	Solid tumor	1
 BL-M07D1	Monospecific	HIRE-ADC	Solid tumor	1
 SI-F019	Viral entry decoy	Fusion protein	COVID-19	1

Find out more about pipeline at <https://www.systimmune.com/pipeline>

Global Offices

N/A

Office in Korea

N/A

Pharmaceutical Company

Taiho Oncology, Inc. - Commercial, Medical



Booth : # 12123, # 16086

CONTACT

PHONE : 609-750-5300

Address : 101 Carnegie Center, Suite
101 Princeton, New Jersey 08540, USA

WEBSITE :

<https://www.taihooncology.com/us/>

No. of Employees : 165

Revenue : \$55.5M

■ About Taiho Oncology, Inc. - Commercial, Medical

The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in orally administered anti-cancer agents and has a growing pipeline of antimetabolic and selectively targeted anti-cancer agents. A subsidiary of Taiho Pharmaceutical Co., Ltd., Taiho markets its medicines for a range of tumor types in the U.S. and oversees its parent company's European and Canadian operations in Zug, Switzerland and Oakville, Ontario, Canada.

■ Pipeline

COMPOUND/ MOA	INDICATION	DEVELOPMENT STAGE	LINKS
¹TRIFLURIDINE AND TIPIRACIL Thymidine-based nucleoside analogue and thymidine phosphorylase inhibitor	Colorectal cancer in combination with bevacizumab	PHASE 3	Link
²FUTIBATINIB FGFR 1-4 inhibitor	Urothelial cancer in combination with pembrolizumab	PHASE 2	Link
	Non-small cell lung cancer with KRAS mutations in combination with binimetinib	PHASE 2	Link
ZIPALERTINIB Tyrosine Kinase Inhibitor of EGFR exon 20 insertion mutations	Non-Small Cell Lung Cancer (Phase 1/2)	PHASE 2	Link
TAS0612 S6K, AKT, RSK inhibitor	Solid Tumors	PHASE 1	Link
TAS2940 ERBB inhibitor	Solid Tumors	PHASE 1	Link

Find out more about pipeline at

<https://www.taihooncology.com/us/science/product-pipeline/>

Global Offices	Office in Korea
Canada, Switzerland, Netherlands, Japan, Singapore, China and United Kingdom	N/A

Pharmaceutical Company

Takeda



Booth : # 10153

CONTACT

PHONE : +81-3-3278-2111

Address : 1-1, Nihonbashi-Honcho 2-
chome, Chuo-ku, Tokyo
103-8668, Japan

WEBSITE : <https://www.takeda.com/>

No. of Employees : 49,578 (2019)


Revenue : ¥1,770,531 million (2018)

About Takeda

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. Our therapies for hematologic cancers and solid tumors have helped transform the treatment landscape for previously underserved patients. Building on this leadership, we are advancing a pipeline focused on the power of innate immunity. Our goal is to introduce new classes of immunotherapies that can lead to deep, durable responses so more patients can benefit from innovative medicines.

Pipeline

10 LATE-STAGE DEVELOPMENT PROGRAMS WITH UPCOMING NME FILING AND EXPANSION OPPORTUNITIES



Find out more about pipeline at <https://www.takeda.com/what-we-do/research-and-development/our-pipeline>

Global Offices

- 3 offices in Japan
- 12 offices in America
- 30 offices in Europe
- 17 offices in Asia

Office in Korea

Takeda Pharmaceuticals Korea
Co., Ltd.
Address: 37F, Lotte World Tower,
Olympic-Ro 300, Songpa-gu,
Seoul 05551, Korea
PHONE : +82-2-3484-0800

Pharmaceutical Company

Telix Pharmaceuticals



Booth : # 28141

CONTACT

Email: info@telixpharma.com

PHONE : (571) 294-4646

Address : 55 Flemington Road
North Melbourne, VIC, Australia, 3051

WEBSITE : <https://telixpharma.com/>

No. of Employees : 60

Revenue : \$5.3M

■ About Telix Pharmaceuticals

Telix Pharmaceuticals, established in 2018 and headquartered in North Melbourne, Australia, is a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States.

■ Pipeline

Prostate	PSMA ¹	PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
Small molecule	⁶⁸ Ga	TLX591-CDx (⁶⁸ Ga-PSMA-11, Ilucix [®])			Imaging
Antibody	¹⁷⁷ Lu	TLX591 (¹⁷⁷ Lu-rosopitamab)			Therapy
Antibody	²²⁵ Ac	TLX592 (²²⁵ Ac-RADmAb [®])			Therapy (2 nd Gen)
Small molecule	^{99m} Tc	TLX599-CDx (^{99m} Tc-IPSMa)*			Imaging / Surgery
Small molecule	⁶⁸ Ga	TLX591-Sx (⁶⁸ Ga-PSMA-IRDye)			Imaging / Surgery
Kidney	CAIX ²	PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
Antibody	⁸⁹ Zr	TLX250-CDx (⁸⁹ Zr-girentuximab)			Imaging
Antibody	¹⁷⁷ Lu	TLX250 (¹⁷⁷ Lu-girentuximab)			Therapy

Find out more about pipeline at <https://telixpharma.com/our-portfolio/pipeline/>

Global Offices

Japan, USA and Belgium

Office in Korea

N/A

Pharmaceutical Company

TerSera Therapeutics, LLC



Booth : # 21113

CONTACT

Email : bd@tersera.com.

PHONE : (888) 600-8116

Address : TerSera Therapeutics LLC
Main Office Location
520 Lake Cook Road,
Suite 500
Deerfield, IL 60015, USA

WEBSITE : <https://www.tersera.com/>

No. of Employees : 135

Revenue : \$1.9M

■ About TerSera Therapeutics, LLC

TerSera Therapeutics is a specialty pharmaceutical company headquartered in suburban Chicago with a focus on select therapeutic areas, including Oncology, and Pain and Inflammation. Our mission is to develop products which truly make a difference for patients. Our focus is to bring intelligent solutions to our customers that go beyond the therapy itself in order to provide improved patient outcomes.

■ Product

 Ergomar® Sublingual Tablets, 2mg <small>(Ergotamine Tartrate Sublingual Tablets, USP)</small>	Product Website Prescribing Information
 PRIALT® <small>(ZICONOTID) INTRATHECAL INFUSION</small>	Product Website Prescribing information
 Quzyttir™ <small>Cetirizine HCl Injection</small>	Product Website Prescribing information
 VARUBI® <small>rolapitant</small>	Product Website Prescribing Information
 XERMELO® <small>(telotristat ethyl) tablets, 250 mg</small>	Product Website Prescribing Information

Find out more about products at <https://www.tersera.com/>

Global Offices	Office in Korea
TerSera Canada Inc. 675 Cochrane Drive, East Tower Address : Suite 600 Markham, Ontario L3R 0B8 PHONE : (888) 568-8556	N/A

Pharmaceutical Company

TOLMAR Pharmaceuticals Inc.



Booth : # 18049

CONTACT

Email : info@tolmar.com

PHONE : 1-877-986-5627

Address : Tolmar Pharmaceuticals, Inc.
485 W. Half Day Road, Suite 400
Buffalo Grove, IL 60089, USA

WEBSITE : <https://www.tolmar.com/>

No. of Employees : 700

Revenue : \$236.3M

■ About TOLMAR Pharmaceuticals Inc.

Tolmar is committed to the development, approval, and commercialization of specialty pharmaceutical products dedicated to advancing patient care in urology.

The Tolmar portfolio includes specialty products for urology, oncology and dermatology. The invention, development and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) delivers innovation and commitment to the urology, oncology and hospital communities, providers and patients. Technology-driven development and high-quality manufacturing capabilities established Tolmar as a leading player for topical generics in the field of dermatology.

■ Pipeline

TREATMENTS IN DEVELOPMENT	PHASE 1	PHASE 2	PHASE 3	PHASE 4
Dermatology				
Prostate Cancer				
Pediatric Endocrinology				
Men's Health				

Find out more about pipeline at <https://www.tolmar.com/science/research-development>

Global Offices	Office in Korea
N/A	N/A

Pharmaceutical Company

TriSalus Life Sciences



Booth : # 13113

CONTACT

Email : info@trisalushifesci.com

PHONE : (415) 336-8917

Address : HQ Westminster, CO
TriSalus Life Sciences
6272 W. 91st Ave.
Westminster, CO 80031, USA

WEBSITE : <https://trisalushifesci.com/>

No. of Employees : 41


Revenue : \$8.2M

■ About TriSalus Life Sciences

TriSalus Life Sciences® is an interventional immunotherapy company that seeks to address two of the most significant barriers that limit the effectiveness of current treatments for liver and pancreatic tumors: immunosuppression and high intratumoral pressure.

■ Pipeline

Primary Liver Cancers



*HCC and ICC will be studies in single phase 1b study (separate cohorts in phase 2)

Liver Metastases



Primary Pancreatic Cancers



Find out more about pipeline at <https://trisalushifesci.com/pipeline/>

Global Offices

- Bannockburn, IL
TriSalus Life Sciences
2275 Half Day Road, Ste. 160
Bannockburn, IL 60015
- Cranston, RI
TriSalus Life Sciences
1000 Chapel View Blvd.
Cranston, RI 02920

Office in Korea

N/A

Pharmaceutical Company

UroGen Pharma Inc.



Booth : # 25101

CONTACT

Email : info@urogen.com

PHONE : (646) 768-9780

Address : 400 Alexander Park Dr Fl 4,
Princeton, New Jersey, 08540, United
States

WEBSITE : <https://www.urogen.com/>

No. of Employees : 192


Revenue : \$54.1M

■ About UroGen Pharma Inc.

UroGen is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated because patients deserve better options. Our vision to pioneer new treatments is grounded in our innovative drug delivery technology platform RTGel™, our promising pipeline and a collaborative drive for bold results.

■ Pipeline

Our Current Pipeline



Find out more about pipeline at <https://www.urogen.com/our-pipeline-and-partners/>

Global Offices	Office in Korea
N/A	N/A

Pharmaceutical Company

Y-mAbs Therapeutics, Inc.



Booth : # 24115

CONTACT

Email : info@ymabs.com

PHONE : (212) 847-9841

Address : 230 Park Ave Ste 3350, New York City, New York, 10169, United States

WEBSITE : <https://ymabs.com/>

No. of Employees : 148

Revenue : \$40M

About Y-mAbs Therapeutics, Inc.

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

Pipeline

Broad and Advanced Clinical Product Development Program

Study	Therapeutic Area	Preclinical	Phase 1	Phase 2	Phase 3/Pivotal Study	Submitted for approval	Next Anticipated Milestone
Naxitamab							
201	Relapsed/Refractory High-Risk Neuroblastoma (Pediatric/Adult)		Ongoing pivotal Phase 2 trial				2020-FDA Approved
12-230	Relapsed/Refractory High-Risk Neuroblastoma (Pediatric) (A MSKCC IND)		Completed Phase 2 trial				2020-FDA Approved
16-1643	Front-Line High-Risk Neuroblastoma (Pediatric) (A MSKCC IND)		Completed Phase 2 trial				
15-096	Relapsed Second-Line Osteosarcoma (A MSKCC IND)		Ongoing Phase 2 trial				
17-251	Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma		Completed Phase 2 trial				
GD2-SADA							
1001	SCLC, sarcoma and melanoma		Ongoing Phase 1 trial				

Find out more about pipeline at <https://ymabs.com/research-development/pipeline/>

Global Offices

- Y-mAbs Therapeutics, Inc.

R&D Laboratories

Address : 111 Ideation Way

Basement Floor, Room C-008

Nutley, NJ 07110, USA

Telephone: +1 646 885 8505

- Y-mAbs Therapeutics A/S

Address : Agern Allé 11, ground floor

2970 Hørsholm, Denmark

Telephone.: +45 70 26 14 14

Office in Korea

N/A